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Stellingen behorende bij het proefschrift
1. De Amsterdam II criteria zijn uitermate geschikt voor het uitsluiten  van Lynch 
syndroom, maar niet voor het aantonen ervan. (dit proefschrift)
2. In vrouwelijke MSH6 mutatiedragers moet endoscopische surveillance vanaf de 
leeftijd  van 30 jaar beginnen. (dit proefschrift)
3.	 Endoscopische	 surveillance	 met	 autofluorescentie	 resulteert	 in	 een	 verhoogde	
detectie van adenomen in patiënten met Lynch syndroom. (dit proefschrift)
4. Het gebruik van predictiemodellen in de medische praktijk kan bijdragen tot een 
verbeterde opsporing van Lynch syndroom. (dit proefschrift)
5. Personen met een hoog risico op mutatie dragerschap zijn eerder geneigd tot het 
ondergaan van pre-symptomatisch mutatie analyse. (dit proefschrift)
6. Blootstelling aan zonlicht verhoogt het risico op huidkanker maar verlaagt het 
risico op darmkanker. 
(van der Rhee, Eur J Cancer, 2006)
7. Als artsen dagelijks 2 artikelen zouden lezen van de 6 miljoen medische artikelen 
die jaarlijks gepubliceerd worden, lopen ze na 1 jaar 82 eeuwen achter. 
(Miser, J. Am. Board Fam. Pract,1999)
8. Statistics are like swim-wear: what they reveal is suggestive but what they conceal 
is vital. (Mahajan, Lancet, 2007) 
9.	 Klein	is	fijn,	aangezien	korte	mensen	langer	leven	dan	lange	mensen.	
(Samaras, Life Sci, 2003)
10. Luister naar ieders kritiek maar behoud uw eigen oordeel. 
(William Shakespeare, 1564-1616 n.C.)
11. In tegenstelling tot een veelvuldige vraag bij een promotie vraagt men op een 
begrafenis niet wanneer jij aan de beurt bent.
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 1OuTLINE OF THE THESIS
Lynch syndrome is the most common hereditary colorectal cancer syndrome, responsible for 
3-5% of all colorectal cancer (CRC) cases. In addition, tumors of the endometrium, ovaries, 
stomach, small bowel, biliary tract, urinary tract, skin and brain occur at higher frequencies 
compared to the general population. Mutations in at least four different mismatch repair (MMR) 
genes, including MLH1, MSH2, MSH6 and PMS2, are the underlying defect in Lynch syndrome. 
The introduction in chapter 2 gives a general overview of different aspects of Lynch syndrome. 
Clinical features, cancer risks, diagnostic strategies, surveillance and management of Lynch 
syndrome are discussed. The identification of Lynch syndrome is still suboptimal, mainly due 
to the lack of specific diagnostic features. Early identification of Lynch syndrome is important 
for optimal surveillance.
Chapter 3 characterizes the cumulative lifetime risk of Lynch syndrome associated cancer in 
mutation carriers originating from 67 Lynch syndrome families. The risks for the three different 
mutation carriers, MLH1, MSH2 and MSH6, is evaluated.
In chapter 4, the presence of germline mutations in MLH1, MSH2 and MSH6 is studied in 108 
families referred for diagnostics for Lynch syndrome. We evaluate the Amsterdam Criteria II 
and the revised Bethesda guidelines as diagnostic tools to identify MLH1, MSH2, as well as 
MSH6 mutations.
Another tool to optimize mutation detection are mutation prediction models. In chapter 5 five 
different mutation prediction models are being externally validated and evaluated for use in 
clinical practice. 
Once a germline mutation is detected in a family risk carriers in this family can be identified. 
Chapter 6 describes the use of germline mutation analysis in high-risk subjects originating 
from Lynch syndrome and other hereditary colorectal carcinoma families. Colonoscopic surveil-
lance in Lynch syndrome is important in order to prevent the development CRC in carriers of a 
predisposition for Lynch syndrome. In chapter 7 an advanced endoscopic modality, autofluores-
ence endoscopy (AFE), is being compared with standard white light endoscopy (WLE) for the 
detection of adenomatous lesions in high risk subjects. 
Finally, the general discussion in chapter 8 gives an overview of the thesis and discusses the 
new insights in the detection and surveillance of Lynch syndrome. Also, recommendations and 
suggestions for future research are made.

Chapter 2
General introduction
Part of this chapter has been published under the title:
Detection and management of hereditary non-polyposis colorectal cancer 
(Lynch syndrome).
Aliment Pharmacol Ther. 2007;26 Suppl 2:101-11.
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INTRODuCTION
Colorectal cancer (CRC) is a common disease in Western populations, with a typical onset above 
60 years. The majority of CRC are sporadic, and have a multifactorial etiology. However, in 
15-20% of all CRC cases inherited genetic factors are expected to be a major underlying cause of 
the disease. The majority of these cases are classified as familial CRC. In familial CRC there is a 
clear familial history of CRC but a disease causing mutation cannot be found. In the remainder, 
an underlying mutation can be found. The most readily distinguished hereditary CRC syndrome 
is Familial Adenomatous Polyposis (FAP). This syndrome is caused by mutations in the APC 
gene and is characterized by the presence of a large number (> 100) of adenomatous polyps in the 
colon. An attenuated form of FAP, AFAP, is characterized by the presence of fewer adenomatous 
polyps (< 100). Furthermore, in patients with AFAP CRC develops at a more advanced age (on 
average 15 years later) than classical FAP and the adenomas have a predilection to the right side 
of the colon.1 In patients with AFAP, the APC mutation is mostly found at the 5’ or 3’ part of the 
APC gene. MUTYH associated polyposis (MAP) is another polyposis syndrome with a similar 
clinical phenotype as AFAP.2 This syndrome is caused by a mutation in the MUTYH gene, which 
is a base-excision repair gene.3 MAP, however, has an autosomal recessive heritance pattern and 
the risk of developing CRC remains unclear. A polyposis syndrome is diagnosed in approxi-
mately 1% of all CRC cases.4 The most common dominant inherited CRC syndrome is Lynch 
syndrome, also known as hereditary non polyposis colorectal cancer (HNPCC). This syndrome 
is caused by mutations in the mismatch repair genes (MMR), MLH1, MSH2, MSH6 and PMS2. It 
is characterized by a high risk of colorectal and endometrial cancer, but also other tumors occur. 
Lynch syndrome is responsible for 2-5% of all CRC cases.5 However, unlike (A)FAP and MAP 
the diagnosis of Lynch syndrome is hampered by the absence of specific diagnostic features, 
such as the presence of many adenomatous polyps in the colon. This chapter will focus on the 
clinical identification and management of Lynch syndrome.
History
The first Lynch syndrome family was reported in 1913 by A.S. Warthin. He described the family 
of his seamstress, known as ‘cancer family G’.6 Warthin was a pathologist at the University of 
Michigan, and recognized the presence of familial cancer in this family. Warthin wrote a follow 
up report about cancer family G 12 years later and noted that most of the cancers occurred in 
the stomach, colon and uterus.7 In 1936, two of his colleagues provided further follow up of this 
family.8 Lynch described two additional families, families N and M (as they came from Nebraska 
and Michigan) in 1966 and revisited family G in 1966 and 1971.9, 10 In the mid-eighties, Finnish, 
Dutch and Italian investigators started to search for Lynch syndrome families in their respective 
countries.11-13 In 1989, the International Collaborative Group (ICG) was set up to promote inter-
national research on the Lynch syndrome.14 At the time of the establishment of the International 
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Collaborative Group the name Lynch syndrome was largely unknown. This was the reason to 
propose a new name, Hereditary Non Polyposis Colorectal Cancer (HNPCC), explaining which 
tumor is mainly involved in the disease.15 Such a name might promote the recognition of the 
syndrome. Nowadays the syndrome is well defined and well known worldwide which made the 
reintroduction of the term Lynch syndrome appropriate.
molecular basis of Lynch syndrome
Lynch syndrome is caused by germline mutations in mismatch repair (MMR) genes. In 1993 
germline mutations in the MMR gene MSH2 were found 16 and in the following years germline 
mutations in the MLH1, MSH6 and PMS2 genes.17-20
The protein products of the MMR genes are involved in correction of mismatches and small 
insertion/deletion loops that arise during DNA replication, but also recognize exogenous muta-
tions and are involved in transcription-coupled repair.21-24 Two different MutS-related heterodi-
meric complexes are responsible for mismatch recognition: MSH2-MSH3 and MSH2-MSH6. 
After mismatch binding, a heterodimeric complex of MutL-related proteins, MLH1-PMS2 
or MLH1-MLH3, is recruited and this initiates the actual mismatch repair. Mismatch repair 
deficiency gives rise to microsatellite instability (MSI). Microsatellites are simple repetitive 
DNA sequences that are found throughout the genome. A National Cancer Institute workshop 
recommended five informative markers for MSI-analysis in colorectal cancers.25 Using these 
markers more than 90% of colorectal cancer from patients with Lynch syndrome exhibit MSI in 
contrast with about 15% of sporadic CRC, making MSI a hallmark of Lynch syndrome.5
Clinical features
Autosomal dominant inheritance is one of the features of Lynch syndrome (Table 1 and Figure 
1). In contrast with familial adenomatous polyposis in which approximately one-fourth of cases 
Table 1. Features of the Lynch syndrome
Autosomal dominant inheritance
Associated cancers: cancer of colorectum, stomach, small bowel, biliary tract, uroepithelial tract, ovary, endometrium, brain, skin 
(sebaceous adenoma)
Development of cancer at an early age
Development of multiple cancers
Features of colorectal cancer: predeliction for proximal location, improved survival, multiple colorectal cancers, poorly 
differentiated tumors and Crohn’s-like infiltration of lymphocytes
Features of adenomas: the numbers vary from one to a few, increased proportion of adenomas with a villous growth pattern, high 
degree of dysplasia, rapid progression from adenoma to carcinoma
High frequency of microsatellite instability
Immunohistochemistry: loss of MLH1, MSH2, MSH6 and PMS2 protein expression
15
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is caused by a de novo APC-gene mutation, Lynch syndrome based on a de novo mismatch 
repair gene mutation has been rarely reported.26-28 
As mentioned before, predisposed individuals from Lynch syndrome families have an in-
creased risk of developing CRC.29-31 The main precursors of CRC are adenomatous polyps.32 In 
predisposed individuals to Lynch syndrome adenomas appear to develop at the same rate as in 
individuals in the general population, but these adenomas develop at an earlier age, have more 
villous components and are more dysplastic than adenomas detected in the general population. 
Furthermore, the adenomas in predisposed individuals seem to progress more rapidly (2 to 3 
years) to invasive colorectal cancer compared to those in the general population (8 to 10 years).33 
Therefore, colorectal cancer in Lynch syndrome mutation carriers is often diagnosed at an early 
age, and synchronous and metachronous CRC are more common. Also, unlike in the general 
population, the majority of these CRC is located in the proximal colon.34, 35 Specific pathological 
characteristics of Lynch syndrome colorectal tumors have been identified but none of them 
are pathognomic. These features include poor differentiation, presence of mucinous and signet 
cells, medullary features, peritumoral lymphocytic infiltration, Crohn’s like reaction, and tumor 
infiltrating lymphocytes mixed with tumor cells.36-38
Lynch syndrome mutation carriers are also at higher risk for other tumors including endome-
trial cancer (after CRC the most common cancer in Lynch syndrome patients) and to a lesser 
extent other cancers such as tumors of the stomach (particularly in Asian countries such as Japan 
CRC 56 
CRC 38 
CRC 29SmB 47CRC 53 CRC 60
EC 44 CRC 33 CRC 47
EC 31 
 
Figure 1. Pedigree of family with classical Lynch syndrome
CRC = colorectal cancer
EC = endometrial cancer
SmB = small bowel cancer
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and Korea), small bowel, ovary, upper uroepithelial tract, biliary tract, skin and brain.29-31, 39 In 
the presence of skin or brain tumors the phenotype is also addressed to as Muire-Torre syndrome 
and Turcot syndrome respectively.
Lynch syndrome associated colorectal tumors are adenocarcinomas. The endometrial cancers 
seen in Lynch syndrome are mostly of the endometroid subtype 40, whereas ovarian cancers are 
serous or mucinous.30, 41 Gastric cancers are generally of the intestinal type.36, 42, 43 With respect 
to tumors of the urinary tract, transitional cell carcinomas are associated with Lynch syndrome, 
localized in the ureter and renal pelvis but surprisingly not in the bladder.44, 45 The skin tumors in 
Lynch syndrome are mostly sebaceous adenomas and adenocarcinomas, while the brain tumors 
are predominantly glioblastomas.46 
Cancer risks in Lynch syndrome
Lynch syndrome has a variable phenotype with respect to the tumor site, age of onset and the 
penetrance. Several studies have evaluated the cancer risks in Lynch syndrome. A summary of 
these studies is presented in Table 2.30, 39, 47-56 The cancer risks in Lynch syndrome are associated 
with the affected MMR gene. In MLH1 and MSH2 mutation carriers the described CRC risk at 
the age of 70 yrs ranges between 28-75% in males and 24-52% in females. 
The mean age of CRC onset in MLH1 and MSH2 mutation carriers is approximately 45 years 
30, 39, 47-56 Only few studies report the cumulative risk of CRC in MSH6 mutation carriers.50, 55 The 
risk of CRC at the age of 70 years in male and female MSH6 mutation carriers is respectively 
60-70% and 30-40%. The age of diagnosis of CRC in MSH6 mutation carriers is an average 5-10 
years delayed compared to MLH1 or MSH2 carriers. The risk for developing endometrial cancer 
in female MSH6 mutation carriers is 60-70%, while this is lower in MLH1 and MSH2 mutation 
Table 2. Life time cancer risks in Lynch syndrome
Affected Mismatch repair gene
Cancer type MLH1+MSH2 MSH6 PMS2
Colorectal cancer (male) 28-75% 60-70-% 15-20%
Colorectal cancer (female) 24-52% 30-40% 15-20%
Endometrial cancer 27-60% 60-70% 15%
Small bowel cancer 4-7% n.a.
25-32%*
Gastric cancer 2-13% n.a.
Ovarian cancer 3-13% n.a.
Biliary tract 4% n.a.
Upper urothelial tract 1-12% n.a.
Brain 1-4% n.a.
n.a. = not available
* all other Lynch syndrome-associated cancers
Average life time risk based on the studies of Aarnio et al.30, Dunlop et al.47, Hampel et al.48, Hendriks et al.49, Plaschke et al.50, Quehenberger et 
al.51, Vasen et al.39, 52-54, 57, Barrow et al.55, 56
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carriers (27-60%). Furthermore, the mean age of onset of endometrial cancer seams slightly 
lower in female MSH6 mutation carriers compared to MLH1 or MSH2 mutation carriers (54 
years vs. 59 years). The risk of other Lynch syndrome associated tumors usually does not exceed 
15% in MLH1 and MSH2 mutation carriers. In MSH6 mutation carriers these risks are at present 
largely unknown. So far, only one study has reported on data regarding cancer risk in PMS2 
mutation carriers.57 The reported risk for developing colorectal cancer was 15-20%, while the 
risk of endometrial cancer was 15%. The risk for other Lynch syndrome associated cancer was 
25-32%, which is much higher than in MLH1, MSH2 or MSH6 mutation carriers. More studies 
evaluating the cancer risks in MSH6 and PMS2 mutation carriers are needed.
It should be noted that these risks could possibly be underestimated because some studies 
evaluated families that were selected by using the Amsterdam criteria 52, or by including both 
carriers as well as non carriers.51 On the other hand, the risks might also be biased because high 
risk families are being referred to a clinical genetic department, so called referral bias, while 
families without an apparent clustering of colorectal cancer are less frequently referred.
Diagnosis of Lynch syndrome
Clinical diagnostic criteria
Identification of subjects carrying a MMR mutation is important as surveillance can be restricted 
to these individuals, while those without a gene defect can be reassured and spared from sur-
veillance. Surveillance in Lynch syndrome is important because it reduces the incidence and 
mortality of colorectal cancer.58-61 Currently, the Amsterdam criteria II and revised Bethesda 
criteria are used in clinical practice to select individuals for further analysis.
The Amsterdam criteria were formulated in 1990 by the International Collaborative Group 
on HNPCC.15 However, in the following years various studies provided evidence that Lynch 
syndrome was also associated with extracolonic tumors. This was the reason to propose a new 
set of criteria that include various extracolonic cancers, the Amsterdam criteria II (Table 3).62 
These criteria are used in clinical practice as a selection criterion for mutation analysis in the 
MMR genes, however these criteria are too stringent to identify all Lynch syndrome families. 
Families suspected of Lynch syndrome but not fulfilling these criteria should not be falsely 
reassured and excluded from genetic counseling, DNA testing or surveillance. 
The Bethesda criteria were formulated in 1996 and updated to the Revised Bethesda criteria in 
2004 (table 2).25, 35, 63 The Bethesda criteria were formulated for the identification of tumors that 
should be tested for MSI in order to select patients for subsequent MMR gene mutation analysis. 
Like the Amsterdam criteria II, the revised Bethesda criteria do not exclude a hereditary factor 
for CRC. Whether the Amsterdam II and revised Bethesda criteria are adequate to identify Lynch 
syndrome patients is established by determining the proportion of cases with a MMR gene muta-
Chapter 2
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tion that would be missed using these criteria in a series of unselected CRC cases. One study 64 
evaluated six studies 5, 65-69 in which either MSI or IHC analysis or both tests were performed as 
the primary screening tool in prospective, unselected series of colorectal cancer patients. The six 
studies showed that the sensitivity of the Amsterdam criteria II for detection of Lynch syndrome 
MLH1 and MSH2 mutation carriers was approximately 40%, while the sensitivity of the revised 
Bethesda criteria was approximately 90%. This means that especially the Amsterdam criteria 
II miss a large proportion of MLH1 and MSH2 mutation carriers.70 These studies and our own 
data (this thesis) indicate that the Amsterdam II and revised Bethesda criteria are suboptimal 
for the identification of Lynch syndrome mutation carriers, especially in families with a milder 
phenotype such as MSH6 and probably also PMS2 families.
Mutation prediction models
In recent years several models to predict the likelihood of carrying a germline mutation have 
been developed.71-75 Mutation prediction models predict the probability of a mutation using 
logistic regression or Bayesian methods. These models use information based on personal and 
family history as input to predict the probability of mutation carriership. 
A major advantage of prediction models is that these models give a quantitative estimation 
of the likelihood of mutation carriership instead of a bivariate (yes/no) assessment as provided 
by the clinical diagnostic criteria. Mutation prediction models are thus potentially useful in 
clinical practice to optimize the identification of Lynch syndrome. The key issues involving 
these models are their performance in clinical practice and their applicability in specific patient 
Table 3. The Amsterdam Criteria II 62 and revised Bethesda criteria 35
Amsterdam criteria II
There should be at least three relatives with a Lynch syndrome  associated tumor (CRC, endometrial, small bowel, ureter/renal 
pelvis cancer); all of the following criteria should be present:
• one should be a first degree relative of the other two
• at least two successive generations should be affected
• at least one should be diagnosed before age 50 years
• all tumors should be verified by pathological examination
• FAP should be excluded in the CRC case
Revised Bethesda criteria
• CRC < age 50 years
• presence of synchronous / metachronous Lynch syndrome-related cancer*, regardless of age
• CRC with specific pathological features < 60 years**
•  CRC diagnosed in one or more 1st degree relatives with an Lynch syndrome- related cancer, with 1 of the diagnosis under age 
50 years
• CRC in two or more 1st or 2nd degree relatives with an Lynch syndrome related cancer, regardless of age
* Lynch syndrome-related cancer: CRC, endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, biliary tract, brain, sebaceous gland 
and small bowel carcinoma.
* *tumor infiltrating lymphocytes, Crohn’s-like lymphocyte reaction, mucinous/signet ring differentiation or medullary growth pattern.
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groups. However, most of these models are based on samples of Caucasian populations with 
European ancestry and further validation in other ethnic groups is necessary. Furthermore, the 
performance of these models has been evaluated in the same study setting which formed the basis 
for their development. External validation is necessary to study generalizability of these models. 
Data concerning the performance of these models in a population-based cohort are sparse. One 
study has evaluated the Premm1,2 model in a population based cohort of 1222 CRC patients 
(the EPICOLON cohort). In this study cohort, the Premm1,2 model identified all the MLH1 and 
MSH2 mutation carriers, indicating a good performance of this model.76 However, the number 
of identified mutations (n=8) was very low, limiting the reliability of this study. Furthermore, the 
Premm1,2 model is not able to identify MSH6 and PMS2 mutation carriers. Another study used 
the same EPICOLON cohort to compare the Premm1,2 model with the Edinburgh model 71 and 
reported a similar performance of both models.77
Microsatellite instability analysis (MSI) & immunohistochemistry (IHC) 
As mentioned before MSI is a hallmark of Lynch syndrome. Using the international set of 
recommended markers (D2S123, D5S346, D17S250, BAT25 and BAT26) more than 90% of 
Lynch syndrome-associated CRC and about 15% of sporadic CRC exhibit microsatellite in-
stability.22, 78-83 Comparing the marker size in normal and tumor DNA from the same individual 
tumors is scored as MSI-high if at least two of the markers show instability, MSI low if one 
marker shows instability, or MSI stable if none of the markers shows instability. The current 
standard method for MSI analysis is relatively time consuming, laborious and expensive, due to 
the need to compare allelic profiles between tumor and matching germline DNA. However, new 
MSI analysis methods such as the fluorescent multiplex PCR of mononucleotide repeats and the 
computerized fragment analysis method are promising. This alternative simple and straightfor-
ward MSI analysis system of mononucleotide microsatellite repeats can identify MSI-H tumors 
with a high sensitivity and specificity. An advantage of these systems is that comparison of 
tumor with matching germline DNA is unnecessary. Studies evaluating these new MSI analysis 
system are promising, but further validation is needed.84, 85
MSI analysis can be performed in DNA extracted from paraffin-wax embedded tumors. To 
optimize MSI analyses good quality of tumor tissue is warranted and an experienced molecular 
laboratory/pathologist is needed. It should also be noted that an MSI-stable phenotype does not 
exclude Lynch syndrome, because of the possibility of a phenocopy. In proven Lynch syndrome 
families, frequently tumors are encountered with no indication of MSI. These individuals could 
have developed, for example, a CRC or endometrial carcinoma because these tumors have a 
relatively high prevalence in the population.86, 87 When a strong suspicion for Lynch syndrome 
remains in spite of a MSI stable tumor, MSI analysis on a second tumor in the family may be 
considered.
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MSI analysis is not suitable to predict which of the MMR genes is affected, but this can be 
demonstrated by further IHC analysis. For this analysis, specific antibodies are used to visualize 
the presence or absence of MLH1, MSH2, MSH6 and PMS2 proteins in tumor cells compared 
to normal cells. An IHC pattern with absent staining for MLH1 and PMS2 and positive staining 
for MSH2 and MSH6 is indicative for a mutation in MLH1 (Table 4). This pattern is explained 
by the fact that the MLH1 protein forms a heterodimer with the PMS2 protein. In the absence of 
MLH1 protein, the heterodimer will not be formed and the PMS2 protein will degrade resulting 
in the absence of staining of both proteins. Because the MSH2 protein forms a heterodimer 
with MSH6, the specific immunohistochemical pattern observed in tumors of MSH2 mutation 
carriers, comprises absence of staining of MSH2 and MSH6 with normal staining of MLH1 and 
PMS2. In tumors from MSH6 mutation carriers generally only absence of staining of the MSH6 
protein is observed whereas in tumors from carriers of a PMS2 mutation absence of the PMS2 
protein is found. 
However, a tumor with an MSI-high phenotype and absent staining of MLH1 can also be 
caused by hypermethylation of the promotor region of the MLH1 gene, which is found in spo-
radic MSI-high CRC. In 50% of the sporadic CRC with MLH1 promotor hypermethylation 
specific mutations in the BRAF gene are found in the tumor tissue. Therefore, additional BRAF 
analysis and MLH1 promotor methylation analysis can differentiate between a somatic sporadic 
MSI-high CRC and a Lynch syndrome related cancer.88-91
IHC is especially indicative for MMR mutations that result in truncation of the protein, such 
as nonsense, frameshift, splice site mutations and large genomic rearrangements. In case of 
missense mutations, IHC is not always diagnostic as the protein may be (partly) expressed and 
therefore still detected by IHC. Also, the value of IHC largely depends on the quality of the 
nuclear staining and the experience of the pathologist.92-94
Several studies have prospectively evaluated the results of MSI and IHC analysis in CRC tis-
sue for the identification of MMR mutations.67-69, 71, 95-97 The reported sensitivity and specificity of 
MSI in these studies varied between 80%-100% and 70-95% respectively. For IHC, the reported 
sensitivity and specificity were 85-95% and 80-95%, respectively. However, only two of these 
studies evaluated all the known MMR proteins.68, 96 
MSI and IHC analysis is optimally performed on colorectal tumor tissue of the youngest 
patient in the family. Other tumor tissues can be analyzed, however, the value of MSI/IHC in 
Table 4. IHC patterns associated with MLH1, MSH2, MSH6 and PMS2 mutations21, 105
MMR gene mutation
IHC staining MLH1 MSH2 MSH6 PMS2
MLH1 - + + +
MSH2 + - + +
MSH6 + - - +
PMS2 - + + -
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other Lynch syndrome related tumors is largely unknown. An American study evaluated the use 
of MSI and IHC analysis in 543 endometrial tumors in an unselected population.98 Of these 543 
tumors, 98 (18%) were MSI-high and 20 (4%) were MSI-low. An abnormal IHC staining was 
found in 90 (92%) of the MSI-high tumors. In 10 (8%) MSI/IHC positive tumors a MMR gene 
mutation was found. The authors concluded that MSI and IHC analysis is feasible in endometrial 
cancer. However, this study did not fully address the sensitivity and specificity of MSI and IHC 
in endometrial cancer since mutation testing in the MSI negative tumors was not performed. 
Nevertheless, other studies, although smaller, also have shown that MSI and IHC is feasible in 
endometrial cancer.99-101 
Colorectal adenomas can also be used for MSI and IHC analysis, however previous studies 
have shown that not all the colorectal adenomas found in mutation carriers exhibit an MSI-high 
phenotype. This is due to the fact that a MSI-high phenotype is not yet fully manifested in early 
or low grade colorectal adenomas.102-104
A combination of MSI and IHC provides the most optimal selection for mutation analysis, 
however in view of the costs some advocate IHC as the first step.95, 105 As mentioned before 
the revised Bethesda criteria were designed to select CRC patients for MSI / IHC analysis. 
Another strategy would be to perform MSI and IHC on all newly diagnosed colorectal cancer 
and or endometrial cancer cases. The advantage of such a strategy may be that families with 
a mild phenotype would also be identified. Studies evaluating this strategy show promising 
results 106, 107, but more studies are needed to evaluate the feasibility, diagnostic yield and cost 
effectiveness of this strategy.
Mutation analysis
To confirm the presence of a mutation in a MMR gene, mutation analysis is performed in DNA 
from blood derived lymphocytes. At this moment there are several techniques available for mu-
tation analysis including direct sequencing, denaturating gradient gel electrophoresis (DGGE) 
with sequencing of aberrant fragments and multiplex ligand dependent probe amplification 
(MLPA) for the detection of large genomic deletions, which occur most frequently in MSH2. 
Mutation analysis is expensive and time consuming. Therefore it is generally performed when 
MSI and IHC analysis are indicative for a germline mutation or if there is a very high suspicion 
of a mutation based on the family history. 
All genomic coding changes are potentially deleterious. However, as opposed to nonsense muta-
tions (which create a stop codon or lead to a frame shift) or those that cause abnormal splicing, 
missense mutations (which lead to the substitution of an amino acid) are usually not considered 
a priori pathogenic. Of all mutations identified in MLH1 and MSH2, 29% and 16%, respectively, 
are missense mutations. A functional test to reliably assess the competence of the mismatch 
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repair proteins is currently not available. Therefore, most missense mutations are designated as 
unclassified variants (UV). These variants cannot be used for diagnostic purposes.
Genetic testing and counseling
The diagnosis of a germline mutation confirming a predisposition to cancer can be complex 
and may have considerable medical and psychosocial consequences.108 Individuals who opt for 
genetic testing should receive genetic counseling and psychosocial guidance. 
Once a mutation has been detected in an affected individual, healthy family members can be 
offered mutation analysis, so called presymptomatic diagnostic testing. A negative genetic test 
may result in emotional relief regarding personal and/or offspring cancer risk, and avoidance 
of unnecessary surveillance. However, feelings of guilt towards affected relatives, so called 
survivor-guilt, may seriously harm inter-familial relations. A positive genetic test may lead to 
emotional distress regarding personal cancer risk and frequent surveillance or considerations for 
prophylactic management. Furthermore, it may have consequences for offspring or the desire 
to have children. Also, a positive result can have financial consequences such as increased 
mortgage and life-insurance costs. The protocol for genetic testing of the American Society 
of Clinical Oncology recommends three sessions with a clinical geneticist.108 During the first 
session the discussed issues include the reasons for testing, the clinical features of the hereditary 
colorectal cancer syndrome, the mode of inheritance, the consequences of the test results, the 
options for surveillance or prophylactic procedures in case of a positive result and the DNA 
testing procedure. In the second session blood samples are taken and during the third session 
the test results are disclosed and if necessary further surveillance strategy discussed. In the 
Netherlands genetic counseling for CRC is offered by the department of Clinical Genetics of the 
University Medical Centers. In clinical practice in the Netherlands blood samples are generally 
taken directly after the first counseling session.
The uptake for genetic testing in Lynch syndrome families varies. A Finnish study reported an 
uptake rate of 75%, while an American study reported a rate of 43%.109, 110 However, both studies 
were performed in a research setting and therefore these studies do not reflect clinical practice. 
We evaluated the uptake in clinical practice and reported uptake rates of 43% and 50%.111, 112  In 
view of the preventative options in risk carriers for Lynch syndrome a higher uptake for genetic 
testing is desirable. The more since a previous study reported that genetic testing improves the 
compliance of colonoscopy surveillance from 19% to 88%.113 and mutation carriers are able to 
cope well with their cancer susceptibility on the short as well on the long term.113-115
Studies at the reasons for risk carriers not to be tested and a better implementation of genetic 
testing in clinical practice are desirable.
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Diagnostic approach in patients suspected of Lynch syndrome
A detailed family history in all patients with cancer is the simplest and most cost-effective way 
to identify hereditary colorectal cancer. Characteristics of hereditary forms of colorectal cancer 
that might be helpful in the differential diagnosis for non hereditary cases include an unusual 
early age of onset, the presence of multiple tumors and the combined occurrence of colorectal 
cancer with endometrial cancer or another Lynch syndrome associated cancer.
In patients who comply to the revised Bethesda criteria MSI and/or IHC analysis should 
be performed on the available tumor tissue.116 However, carcinomas in MSH6 mutation car-
riers, particularly endometrial carcinomas, have been shown to be present with a MSI-stable 
phenotype in a minority that cannot be neglected.86, 117(this thesis) Therefore, if an MSI-stable 
phenotype is found in a family with clustering of endometrial carcinoma, IHC of MSH6 is the 
next step. If IHC is negative for MSH6, mutation analysis follows. If staining is present, MSI 
analysis of a second tumor can be considered. With respect to PMS2 mutations further studies 
are required.
In MSI-H cases with absent staining of MLH1 promotor hypermethylation analysis should be 
performed before germline mutation analysis to exclude sporadic MSI-H cases. 
In cases with a strong positive family history but an MSI stable tumor, MSI analysis on a second 
tumor from the same family is recommended to exclude the possibility of phenocopies. When 
MSI and IHC analysis do not show abnormalities, germline mutation analysis is not useful.118
Surveillance in Lynch Syndrome
Surveillance of the colon
The surveillance program of Lynch syndrome includes colorectal surveillance by biennial 
colonoscopy starting from the age of 20-25 years (Table 5). The rationale for biennial colonos-
copy screening is that the risk for developing an invasive CRC within this two year period is 
small.119, 120 There is evidence that colonoscopy surveillance is effective in reducing the incidence 
and mortality of CRC.58-61 A Finnish study followed 22 Lynch syndrome families during a period 
of 15 years.61 Colonoscopy surveillance at 3-year interval resulted in a 65% decrease in mortality 
and an increased detection of early stage CRC. A decrease in mortality was also found in a 
Table 5. Surveillance guidelines in Lynch syndrome 64
Surveillance Examination Start at age Interval
Colon Colonoscopy 20-25 years 1-2 year
Endometrium Gynaecological examination, transvaginal US 30-35 years 1-2 year
Stomach* Gastroscopy 30-35 years 1-2 year
Urinary tract* Urine cytology 30-35 years 1-2 year
* if stomach or urinary tract cancer runs in the family (more than one case)
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Dutch study that evaluated the Dutch surveillance program for Lynch syndrome.58 This study 
reported a 70% decrease in the standardized mortality ratio for colorectal cancer when one or 
more surveillance colonoscopies were performed. However, interval cancers have been reported 
despite surveillance colonoscopy.121
Currently, colonoscopy surveillance is performed by white light endoscopy, but a recent meta 
analysis including 6 studies with tandem colonoscopies showed an adenoma miss rate of 2% 
for adenomas > 10 mm and even a 26% miss rate for adenomas < 5 mm.122 In Lynch syndrome, 
flat adenomas are particularly prone to malignant transformation compared to adenomas in the 
general population.33, 34 Other endoscopic modalities such as high magnification chromo endos-
copy, narrow band imaging or autofluorescence endoscopy could decrease the adenoma miss 
rate. Chromo endoscopy is a colonoscopic technique in which the colonic surface is sprayed 
with a dye, such as indigo carmine, resulting in an enhanced view of the epithelial surface. Two 
small studies have evaluated the use of high magnification chromo-endoscopy in Lynch syn-
drome patients. A French study evaluated chromo-endoscopy in 36 consecutive asymptomatic 
patients belonging to Lynch syndrome families.123 During white light colonoscopy 7 adenomas 
were detected in five patients and chromo endoscopy detected an additional 11 adenomas in 
eight patients. The adenoma detection rate of chromo-endoscopy was significantly higher (p 
=0.045) than white light colonoscopy. These results were confirmed by a British study, in which 
25 asymptomatic patients fulfilling the modified Amsterdam criteria underwent both conven-
tional and chromo-endoscopy.124 White light colonoscopy detected 11 adenomas and chromo-
endoscopy detected an additional 32 adenomas (p < 0.01). However, chromo-endoscopy is time 
consuming because of the dye spraying. Both narrow band imaging and autofluorescence do 
not need additional dye spraying thus these techniques might be less time consuming. Narrow 
band imaging is another endoscopic modality, in which superficial capillaries in the mucosa are 
highlighted. Neoplasia in the mucosa has an increased vascular density and thus can be easily 
detected by narrow band imaging. So far, only one study has evaluated narrow band imaging for 
colonoscopic surveillance in Lynch syndrome.125 In total 62 patients were evaluated and with 
the use of narrow band imaging the number of patients with adenomas increased with 15% to a 
total of 42%. 
Autofluorescence endoscopy also is another technique which may be used in the colono-
scopic surveillance of Lynch syndrome. The polyp detection rate with autofluorescence may be 
higher 126 than conventional white light colonoscopy. More studies evaluating autofluorescence 
endoscopy and narrow band imaging are needed. Until then, biennial colonoscopy screening 
by conventional high quality magnification white light colonoscopy remains the gold standard.
Surveillance of the endometrium 
Endometrial cancer is the second most common malignancy in Lynch syndrome and therefore 
female mutation carriers are offered endometrial cancer surveillance. The endometrial surveil-
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lance program includes biennial gynaecological examination and transvaginal US examination, 
starting at the age of 30-35 years. However, the effect of endometrial cancer surveillance is 
disputable.127-129 Because of the higher risk of developing endometrial carcinoma in MSH6 muta-
tion carriers, hysterectomy can be suggested in these women after menopause. 
In view of the risk of ovarian carcinoma, the failure of early cancer detection with trans-
vaginal US and determination of the tumor marker CA125, bilateral salpingo-oophorectomy 
may be considered in families with an excess of ovarian carcinoma. Also an ovariectomy can 
be considered in females with a prophylactic hysterectomy.130, 131 The value of surveillance for 
endometrial cancer is not known and further studies need to prove that biennial surveillance 
leads to the detection of premalignant lesions and early cancers. Accurate treatment of women 
with postmenopausal blood loss is probably the most important.
Surveillance of gastric carcinoma and upper urothelial cell carcinoma is recommended if two 
or more tumor cases occur within the family.116 However, the value of this strategy still remains 
unclear. Surveillance guidelines for other Lynch syndrome associated tumors (small bowel, 
ovary, biliary tract, skin and brain) are lacking.
Therapy of colorectal carcinoma in Lynch syndrome
Surgical treatment for colorectal carcinoma
Previous studies have raised the question whether a subtotal colectomy instead of a segmental 
resection might be the preferred treatment in Lynch syndrome patients with a primary CRC.
A Finnish study reported that 15/37 Lynch syndrome patients who underwent a segmental 
colon resection developed a metachronous CRC, compared to 4/17 Lynch syndrome patients 
who underwent a subtotal colectomy.132 An American study reported a metachronous CRC in 
16/70 Lynch syndrome patients who underwent a segmental colon resection versus 0/23 Lynch 
syndrome patients who underwent a subtotal colectomy.133 The results of these studies sug-
gest that a subtotal colectomy is the preferred treatment in Lynch syndrome related CRC. In a 
Dutch study a decision analysis was performed to compare the life expectancy for patients who 
underwent either a subtotal colectomy or a segmental colon resection.134 The authors concluded 
that a subtotal colectomy performed at a young age (< 47 years) would result in an increased 
life expectancy of up to 2.3 years. A subtotal colectomy in a 67 years old patient resulted in an 
increased life expectancy up to only 0.3 years. Based on these findings a subtotal colectomy with 
an ileorectal anastomosis should be the treatment of first choice in young patients (< 60 years) 
presenting with CRC, while in older patients a segmental colon resection might be appropriate. 
Of course, surveillance of the residual colon remains important.
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Chemotherapy
Currently, chemotherapeutic regimes for colorectal cancer include 5FU with or without 
leucovorin, oxaliplatin and irinotecan. The effect of chemotherapy on MSI-high tumors have 
been reported in a few studies.135-139 Most of these studies reported that there was no benefit of 
5FU-based chemotherapy and questioned the benefit of such therapy for patients with MSI-high 
tumors. However, one study was a prospective non randomized study in 244 patients, including 
52 with a MSI-high tumor.135 The authors concluded that patients with an MSI-high tumor that 
received 5FU-based chemotherapy had a better survival. Prospective clinical trials are needed to 
evaluate the effect of different chemotherapeutic regimes in MSI-high tumors.
Chemoprevention in Lynch syndrome
The use of aspirin has been associated with a moderate reduction in the risk of colonic adenomas 
and colorectal cancer in the general population, while resistant starch (an isomer of starch) has 
been associated with an antineoplastic effect.140-143 Therefore, aspirin and resistant starch would 
be a candidate for chemoprevention in Lynch syndrome. Recently, a randomized, placebo con-
trolled trial evaluated the use of aspirin and resistant starch in proven mutation carriers during a 
follow up period of 4 years. Of 693 participants randomly assigned to receive aspirin or placebo, 
neoplasia developed in 66 (18.9%) participants receiving aspirin versus 65 (19%) participants 
receiving placebo. The trial did not report a significant difference between the two groups with 
respect to the development of advanced colorectal neoplasia (7.4% vs. 9.9%, p =0.33). Of the 
727 participants receiving resistant starch or placebo, also no significant difference was reported 
(18.7% vs. 18.4%). Furthermore, the distribution of advanced adenoma and colorectal cancer 
were evenly distributed in both groups. Although the concept of chemoprevention is promising, 
there are currently no chemopreventive agents available for the prevention of colorectal cancer 
in Lynch syndrome.
27
General introduction
Ch
ap
ter
 2
REFERENCES
 1.  Knudsen AL, Bisgaard ML, Bulow S. Attenuated familial adenomatous polyposis (AFAP). A review 
of the literature. Fam Cancer 2003;2:43-55.
 2.  Sampson JR, Dolwani S, Jones S, Eccles D, Ellis A, et al. Autosomal recessive colorectal adenoma-
tous polyposis due to inherited mutations of MYH. Lancet 2003;362:39-41.
 3.  Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, et al. Inherited variants of MYH 
associated with somatic G:C-->T:A mutations in colorectal tumors. Nat Genet 2002;30:227-232.
 4.  Bisgaard ML, Fenger K, Bulow S, Niebuhr E, Mohr J. Familial adenomatous polyposis (FAP): 
frequency, penetrance, and mutation rate. Hum Mutat 1994;3:121-125.
 5.  Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, et al. Incidence of hereditary nonpol-
yposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 
1998;338:1481-1487.
 6.  Warthin AS. Heredity with reference to carcinoma; as shown by the study of cases examined in the 
pathological laboratory of the University of Michigan 1895-1913. 12 ed. 1913:546-555.
 7.  Warthin AS. The further study of a cancer family. 117 ed. 1925:206-212.
 8.  Hauser IJ, Weller CV. A further report on the cancer family of Warthin. 27 ed. 1936:434-449.
 9.  Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ. Hereditary factors in cancer. Study of 
two large midwestern kindreds. Arch Intern Med 1966;117:206-212.
 10.  Lynch HT, Krush AJ. Cancer family “G” revisited: 1895-1970. Cancer 1971;27:1505-1511.
 11.  Mecklin JP, Jarvinen HJ, Peltokallio P. Cancer family syndrome. Genetic analysis of 22 Finnish 
kindreds. Gastroenterology 1986;90:328-333.
 12.  Vasen HF, den Hartog Jager FC, Menko FH, Nagengast FM. Screening for hereditary non-polyposis 
colorectal cancer: a study of 22 kindreds in The Netherlands. Am J Med 1989;86:278-281.
 13.  Ponz De LM, Sassatelli R, Sacchetti C, Zanghieri G, Scalmati A, et al. Familial aggregation of 
tumors in the three-year experience of a population-based colorectal cancer registry. Cancer Res 
1989;49:4344-4348.
 14.  Lynch HT, Cristofaro G, Rozen P, Vasen H, Lynch P, et al. History of the International Collaborative 
Group on Hereditary Non Polyposis Colorectal Cancer. Fam Cancer 2003;2:3-5.
 15.  Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary 
Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424-425.
 16.  Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, et al. The human mutator gene homolog 
MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75:1027-1038.
 17.  Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, et al. Mutation in the DNA mismatch 
repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 
1994;368:258-261.
 18.  Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, et al. Mutation of a mutL homolog 
in hereditary colon cancer. Science 1994;263:1625-1629.
 19.  Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, et al. Germline mutation of 
MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997;17:271-272.
 20.  Akiyama Y, Sato H, Yamada T, Nagasaki H, Tsuchiya A, et al. Germ-line mutation of the hMSH6/
GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res 
1997;57:3920-3923.
 21.  de Jong AE, van Puijenbroek M, Hendriks Y, Tops C, Wijnen J, et al. Microsatellite instability, im-
munohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal 
cancer. Clin Cancer Res 2004;10:972-980.
Chapter 2
28
 22.  Kunkel TA. Nucleotide repeats. Slippery DNA and diseases. Nature 1993;365:207-208.
 23.  Jiricny J. Mediating mismatch repair. Nat Genet 2000;24:6-8.
 24.  Lipkin SM, Wang V, Jacoby R, Banerjee-Basu S, Baxevanis AD, et al. MLH3: a DNA mismatch 
repair gene associated with mammalian microsatellite instability. Nat Genet 2000;24:27-35.
 25.  Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, et al. A National Cancer 
Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: 
development of international criteria for the determination of microsatellite instability in colorectal 
cancer. Cancer Res 1998;58:5248-5257.
 26.  Ripa R, Bisgaard ML, Bulow S, Nielsen FC. De novo mutations in familial adenomatous polyposis 
(FAP). Eur J Hum Genet 2002;10:631-637.
 27.  Desai DC, Lockman JC, Chadwick RB, Gao X, Percesepe A, et al. Recurrent germline mutation in 
MSH2 arises frequently de novo. J Med Genet 2000;37:646-652.
 28.  Kraus C, Kastl S, Gunther K, Klessinger S, Hohenberger W, et al. A proven de novo germline 
mutation in HNPCC. J Med Genet 1999;36:919-921.
 29.  Watson P, Lynch HT. The tumor spectrum in HNPCC. Anticancer Res 1994;14:1635-1639.
 30.  Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, et al. Cancer risk in mutation carriers 
of DNA-mismatch-repair genes. Int J Cancer 1999;81:214-218.
 31.  Park YJ, Shin KH, Park JG. Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in 
Korea. Clin Cancer Res 2000;6:2994-2998.
 32.  Watanabe T, Muto T, Sawada T, Miyaki M. Flat adenoma as a precursor of colorectal carcinoma in 
hereditary nonpolyposis colorectal carcinoma. Cancer 1996;77:627-634.
 33.  Jass JR, Stewart SM. Evolution of hereditary non-polyposis colorectal cancer. Gut 1992;33:783-786.
 34.  Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348:919-932.
 35.  Umar A, Boland CR, Terdiman JP, Syngal S, de la CA, et al. Revised Bethesda Guidelines for 
hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl 
Cancer Inst 2004;96:261-268.
 36.  Lynch HT, Lanspa S, Smyrk T, Boman B, Watson P, et al. Hereditary nonpolyposis colorectal cancer 
(Lynch syndromes I & II). Genetics, pathology, natural history, and cancer control, Part I. Cancer 
Genet Cytogenet 1991;53:143-160.
 37.  Mecklin JP, Jarvinen HJ. Clinical features of colorectal carcinoma in cancer family syndrome. Dis 
Colon Rectum 1986;29:160-164.
 38.  Young J, Simms LA, Biden KG, Wynter C, Whitehall V, et al. Features of colorectal cancers with 
high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of 
tumorigenesis. Am J Pathol 2001;159:2107-2116.
 39.  Ten Kate GL, Kleibeuker JH, Nagengast FM, Craanen M, Cats A, et al. Is surveillance of the small 
bowel indicated for Lynch syndrome families? Gut 2007.
 40.  de Leeuw WJ, Dierssen J, Vasen HF, Wijnen JT, Kenter GG, et al. Prediction of a mismatch repair 
gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours 
from HNPCC patients. J Pathol 2000;192:328-335.
 41.  Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, et al. Genetics, natural history, tumor spec-
trum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterol-
ogy 1993;104:1535-1549.
 42.  Aarnio M, Salovaara R, Aaltonen LA, Mecklin JP, Jarvinen HJ. Features of gastric cancer in heredi-
tary non-polyposis colorectal cancer syndrome. Int J Cancer 1997;74:551-555.
29
General introduction
Ch
ap
ter
 2
 43.  Rodriguez-Bigas MA, Vasen HF, Lynch HT, Watson P, Myrhoj T, et al. Characteristics of small 
bowel carcinoma in hereditary nonpolyposis colorectal carcinoma. International Collaborative 
Group on HNPCC. Cancer 1998;83:240-244.
 44.  Sijmons RH, Kiemeney LA, Witjes JA, Vasen HF. Urinary tract cancer and hereditary nonpolyposis 
colorectal cancer: risks and screening options. J Urol 1998;160:466-470.
 45.  Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 
1993;71:677-685.
 46.  Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, et al. The molecular basis of Turcot’s 
syndrome. N Engl J Med 1995;332:839-847.
 47.  Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, et al. Cancer risk associated with 
germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6:105-110.
 48.  Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, et al. Cancer risk in hereditary nonpol-
yposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005;129:415-421.
 49.  Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, et al. Cancer risk in hereditary 
nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. 
Gastroenterology 2004;127:17-25.
 50.  Plaschke J, Engel C, Kruger S, Holinski-Feder E, Pagenstecher C, et al. Lower incidence of colorec-
tal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations 
compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis 
Colorectal Cancer Consortium. J Clin Oncol 2004;22:4486-4494.
 51.  Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for 
carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 
2005;42:491-496.
 52.  Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, et al. MSH2 mutation carri-
ers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis 
colorectal cancer families. J Clin Oncol 2001;19:4074-4080.
 53.  Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, et al. Cancer risk in families with hereditary 
nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110:1020-1027.
 54.  Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, et al. The risk of extra-colonic, extra-
endometrial cancer in the Lynch syndrome. Int J Cancer 2008;123:444-449.
 55.  Barrow E, Alduaij W, Robinson L, Shenton A, Clancy T, et al. Colorectal cancer in HNPCC: cu-
mulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven 
mutations. Clin Genet 2008;74:233-242.
 56.  Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, et al. Cumulative lifetime incidence of 
extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 
2009;75:141-149.
 57.  Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, et al. The clinical phenotype of Lynch 
syndrome due to germ-line PMS2 mutations. Gastroenterology 2008;135:419-428.
 58.  de Jong AE, Hendriks YM, Kleibeuker JH, de Boer SY, Cats A, et al. Decrease in mortality in Lynch 
syndrome families because of surveillance. Gastroenterology 2006;130:665-671.
 59.  Jablonska M, Reznikova L, Kotrlik J, Svitavsky M, Mikova M, et al. Clinical implications of rec-
ognition of the hereditary non-polyposis colon cancer syndrome (HNPCC) for the early detection of 
colorectal cancer. Sb Lek 1995;96:275-282.
 60.  Vasen HF, Taal BG, Nagengast FM, Griffioen G, Menko FH, et al. Hereditary nonpolyposis colorec-
tal cancer: results of long-term surveillance in 50 families. Eur J Cancer 1995;31A:1145-1148.
Chapter 2
30
 61.  Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, et al. Controlled 15-year trial 
on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gas-
troenterology 2000;118:829-834.
 62.  Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis 
colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on 
HNPCC. Gastroenterology 1999;116:1453-1456.
 63.  Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, et al. A National Cancer 
Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights 
and Bethesda guidelines. J Natl Cancer Inst 1997;89:1758-1762.
 64.  Vasen HF, Moslein G, Alonso A, Bernstein I, Bertario L, et al. Guidelines for the clinical manage-
ment of Lynch syndrome (HNPCC). J Med Genet 2007.
 65.  Debniak T, Kurzawski G, Gorski B, Kladny J, Domagala W, et al. Value of pedigree/clinical data, 
immunohistochemistry and microsatellite instability analyses in reducing the cost of determining 
hMLH1 and hMSH2 gene mutations in patients with colorectal cancer. Eur J Cancer 2000;36:49-54.
 66.  Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, et al. Population-based molecular detec-
tion of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000;18:2193-2200.
 67.  Cunningham JM, Kim CY, Christensen ER, Tester DJ, Parc Y, et al. The frequency of hereditary 
defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum 
Genet 2001;69:780-790.
 68.  Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, et al. Screening for the Lynch syndrome 
(hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352:1851-1860.
 69.  Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, et al. Accuracy of revised Bethesda 
guidelines, microsatellite instability, and immunohistochemistry for the identification of patients 
with hereditary nonpolyposis colorectal cancer. JAMA 2005;293:1986-1994.
 70.  Ramsoekh D, Wagner A, van Leerdam ME, Dinjens WN, Steyerberg EW, et al. A high incidence 
of MSH6 mutations in Amsterdam criteria II-negative families tested in a diagnostic setting. Gut 
2008;57:1539-1544.
 71.  Barnetson RA, Tenesa A, Farrington SM, Nicholl ID, Cetnarskyj R, et al. Identification and 
survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 
2006;354:2751-2763.
 72.  Balmana J, Stockwell DH, Steyerberg EW, Stoffel EM, Deffenbaugh AM, et al. Prediction of MLH1 
and MSH2 mutations in Lynch syndrome. JAMA 2006;296:1469-1478.
 73.  Chen S, Wang W, Lee S, Nafa K, Lee J, et al. Prediction of germline mutations and cancer risk in the 
Lynch syndrome. JAMA 2006;296:1479-1487.
 74.  Wijnen JT, Vasen HF, Khan PM, Zwinderman AH, van der KH, et al. Clinical findings with implications 
for genetic testing in families with clustering of colorectal cancer. N Engl J Med 1998;339:511-518.
 75.  Lipton LR, Johnson V, Cummings C, Fisher S, Risby P, et al. Refining the Amsterdam Criteria and 
Bethesda Guidelines: testing algorithms for the prediction of mismatch repair mutation status in the 
familial cancer clinic. J Clin Oncol 2004;22:4934-4943.
 76.  Balaguer F, Balmana J, Castellvi-Bel S, Steyerberg EW, Andreu M, et al. Validation and extension of 
the PREMM1,2 model in a population-based cohort of colorectal cancer patients. Gastroenterology 
2008;134:39-46.
 77.  Balmana J, Balaguer F, Castellvi-Bel S, Steyerberg EW, Andreu M, et al. Comparison of predictive 
models, clinical criteria and molecular tumour screening for the identification of patients with Lynch 
syndrome in a population-based cohort of colorectal cancer patients. J Med Genet 2008;45:557-563.
31
General introduction
Ch
ap
ter
 2
 78.  Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 
1993;260:816-819.
 79.  Jiricny J. Replication errors: cha(lle)nging the genome. EMBO J 1998;17:6427-6436.
 80.  Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, et al. Genomic instability 
in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 
1993;53:5849-5852.
 81.  Moslein G, Tester DJ, Lindor NM, Honchel R, Cunningham JM, et al. Microsatellite instability 
and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary 
colorectal cancer. Hum Mol Genet 1996;5:1245-1252.
 82.  Aaltonen LA, Peltomaki P, Mecklin JP, Jarvinen H, Jass JR, et al. Replication errors in benign 
and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 
1994;54:1645-1648.
 83.  Lipkin SM, Wang V, Stoler DL, Anderson GR, Kirsch I, et al. Germline and somatic mutation analy-
ses in the DNA mismatch repair gene MLH3: Evidence for somatic mutation in colorectal cancers. 
Hum Mutat 2001;17:389-396.
 84.  Deschoolmeester V, Baay M, Wuyts W, van Marck E, van Damme N, et al. Detection of microsat-
ellite instability in colorectal cancer using an alternative multiplex assay of quasi-monomorphic 
mononucleotide markers. J Mol Diagn 2008;10:154-159.
 85.  Berginc G, Glavac D. Rapid and accurate approach for screening of microsatellite unstable tumours 
using quasimonomorphic mononucleotide repeats and denaturating high performance liquid chro-
matography (DHPLC). Dis Markers 2009;26:19-26.
 86.  Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, et al. Cancer risk in hereditary 
nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. 
Gastroenterology 2004;127:17-25.
 87.  Hendriks YM, Jagmohan-Changur S, van der Klift HM, Morreau H, van Puijenbroek M, et al. 
Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch 
syndrome). Gastroenterology 2006;130:312-322.
 88.  McGivern A, Wynter CV, Whitehall VL, Kambara T, Spring KJ, et al. Promoter hypermethylation 
frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic 
MSI-H colon cancer. Fam Cancer 2004;3:101-107.
 89.  Domingo E, Niessen RC, Oliveira C, Alhopuro P, Moutinho C, et al. BRAF-V600E is not involved 
in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. 
Oncogene 2005;24:3995-3998.
 90.  Raedle J, Trojan J, Brieger A, Weber N, Schafer D, et al. Bethesda guidelines: relation to microsatel-
lite instability and MLH1 promoter methylation in patients with colorectal cancer. Ann Intern Med 
2001;135:566-576.
 91.  Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, et al. Hypermethylation of the 
hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998;58:3455-3460.
 92.  Muller W, Burgart LJ, Krause-Paulus R, Thibodeau SN, Almeida M, et al. The reliability of immu-
nohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal 
cancer (HNPCC)--results of an international collaborative study. Fam Cancer 2001;1:87-92.
 93.  Overbeek LI, Ligtenberg MJ, Willems RW, Hermens RP, Blokx WA, et al. Interpretation of im-
munohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg 
Pathol 2008;32:1246-1251.
Chapter 2
32
 94.  Mangold E, Pagenstecher C, Friedl W, Fischer HP, Merkelbach-Bruse S, et al. Tumours from MSH2 
mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers 
exhibit weak positive MLH1 staining. J Pathol 2005;207:385-395.
 95.  Engel C, Forberg J, Holinski-Feder E, Pagenstecher C, Plaschke J, et al. Novel strategy for optimal 
sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the 
diagnosis of hereditary nonpolyposis colorectal cancer. Int J Cancer 2006;118:115-122.
 96.  Southey MC, Jenkins MA, Mead L, Whitty J, Trivett M, et al. Use of molecular tumor charac-
teristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol 
2005;23:6524-6532.
 97.  Niessen RC, Berends MJ, Wu Y, Sijmons RH, Hollema H, et al. Identification of mismatch repair 
gene mutations in young patients with colorectal cancer and in patients with multiple tumours as-
sociated with hereditary non-polyposis colorectal cancer. Gut 2006;55:1781-1788.
 98.  Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, et al. Screening for Lynch syndrome 
(hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 
2006;66:7810-7817.
 99.  Yoon SN, Ku JL, Shin YK, Kim KH, Choi JS, et al. Hereditary nonpolyposis colorectal cancer in 
endometrial cancer patients. Int J Cancer 2008;122:1077-1081.
 100.  Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, et al. Prospective determination of preva-
lence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 2007;25:5158-5164.
 101.  Walsh MD, Cummings MC, Buchanan DD, Dambacher WM, Arnold S, et al. Molecular, pathologic, 
and clinical features of early-onset endometrial cancer: identifying presumptive lynch syndrome 
patients. Clin Cancer Res 2008;14:1692-1700.
 102.  Muller A, Beckmann C, Westphal G, Bocker ET, Friedrichs N, et al. Prevalence of the mismatch-
repair-deficient phenotype in colonic adenomas arising in HNPCC patients: results of a 5-year 
follow-up study. Int J Colorectal Dis 2006;21:632-641.
 103.  Giuffre G, Muller A, Brodegger T, Bocker-Edmonston T, Gebert J, et al. Microsatellite analysis of 
hereditary nonpolyposis colorectal cancer-associated colorectal adenomas by laser-assisted micro-
dissection: correlation with mismatch repair protein expression provides new insights in early steps 
of tumorigenesis. J Mol Diagn 2005;7:160-170.
 104.  Iino H, Simms L, Young J, Arnold J, Winship IM, et al. DNA microsatellite instability and mis-
match repair protein loss in adenomas presenting in hereditary non-polyposis colorectal cancer. Gut 
2000;47:37-42.
 105.  Hendriks YM, de Jong AE, Morreau H, Tops CM, Vasen HF, et al. Diagnostic approach and manage-
ment of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA 
Cancer J Clin 2006;56:213-225.
 106.  Julie C, Tresallet C, Brouquet A, Vallot C, Zimmermann U, et al. Identification in Daily Practice of 
Patients With Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer): Revised Bethesda 
Guidelines-Based Approach Versus Molecular Screening. Am J Gastroenterol 2008.
 107.  Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, et al. Feasibility of Screening for Lynch 
Syndrome Among Patients With Colorectal Cancer. J Clin Oncol 2008.
 108.   American Society of Clinical Oncology policy statement update: genetic testing for cancer suscep-
tibility. J Clin Oncol 2003;21:2397-2406.
 109.  Aktan-Collan K, Mecklin JP, Jarvinen H, Nystrom-Lahti M, Peltomaki P, et al. Predictive genetic 
testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction. Int J Can-
cer 2000;89:44-50.
33
General introduction
Ch
ap
ter
 2
 110.  Lerman C, Hughes C, Trock BJ, Myers RE, Main D, et al. Genetic testing in families with hereditary 
nonpolyposis colon cancer. JAMA 1999;281:1618-1622.
 111.  Wagner A, Tops C, Wijnen JT, Zwinderman K, van der Meer C, et al. Genetic testing in hereditary 
non-polyposis colorectal cancer families with a MSH2, MLH1, or MSH6 mutation. J Med Genet 
2002;39:833-837.
 112.  Ramsoekh D, van Leerdam ME, Tops CM, Dooijes D, Steyerberg EW, et al. The use of genetic 
testing in hereditary colorectal cancer syndromes: genetic testing in HNPCC, (A)FAP and MAP. Clin 
Genet 2007;72:562-567.
 113.  Wagner A, van K, I, Kriege MG, Tops CM, Wijnen JT, et al. Long term follow-up of HNPCC 
gene mutation carriers: compliance with screening and satisfaction with counseling and screening 
procedures. Fam Cancer 2005;4:295-300.
 114.  van Oosten I, Meijers-Heijboer H, Duivenvoorden HJ, Brocker-Vriends AH, van Asperen CJ, et al. 
Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard 
to coping, illness perceptions, illness experiences, family system characteristics and hereditary 
cancer distress. Patient Educ Couns 2007;65:58-68.
 115.  Aktan-Collan K, Haukkala A, Mecklin JP, Uutela A, Kaariainen H. Psychological consequences of 
predictive genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a prospective 
follow-up study. Int J Cancer 2001;93:608-611.
 116.   Richtlijn Erfelijke Darmkanker 2008. Vereniging Klinische Genetica Nederland; Kwaliteitsinstituut 
voor de gezondheidszorg CBO, 2008.
 117.  Wu Y, Berends MJ, Mensink RG, Kempinga C, Sijmons RH, et al. Association of hereditary 
nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 
germline mutations. Am J Hum Genet 1999;65:1291-1298.
 118.  Kets CM, van Krieken JH, Hebeda KM, Wezenberg SJ, Goossens M, et al. Very low prevalence of 
germline MSH6 mutations in hereditary non-polyposis colorectal cancer suspected patients with 
colorectal cancer without microsatellite instability. Br J Cancer 2006;95:1678-1682.
 119.  Lanspa SJ, Jenkins JX, Cavalieri RJ, Smyrk TC, Watson P, et al. Surveillance in Lynch syndrome: 
how aggressive? Am J Gastroenterol 1994;89:1978-1980.
 120.  de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G, Menko FH, Taal BG, et al. Surveil-
lance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon 
Rectum 2002;45:1588-1594.
 121.  Vasen HF, Nagengast FM, Khan PM. Interval cancers in hereditary non-polyposis colorectal cancer 
(Lynch syndrome). Lancet 1995;345:1183-1184.
 122.  van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, et al. Polyp miss rate determined 
by tandem colonoscopy: a systematic review. Am J Gastroenterol 2006;101:343-350.
 123.  Lecomte T, Cellier C, Meatchi T, Barbier JP, Cugnenc PH, et al. Chromoendoscopic colonoscopy 
for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome. Clin 
Gastroenterol Hepatol 2005;3:897-902.
 124.  Hurlstone DP, Karajeh M, Cross SS, McAlindon ME, Brown S, et al. The role of high-magnification-
chromoscopic colonoscopy in hereditary nonpolyposis colorectal cancer screening: a prospective 
“back-to-back” endoscopic study. Am J Gastroenterol 2005;100:2167-2173.
 125.  East JE, Suzuki N, Stavrinidis M, Guenther T, Thomas HJ, et al. Narrow band imaging for colono-
scopic surveillance in hereditary non-polyposis colorectal cancer. Gut 2008;57:65-70.
 126.  Matsuda T, Saito Y, Fu KI, Uraoka T, Kobayashi N, et al. Does autofluorescence imaging videoen-
doscopy system improve the colonoscopic polyp detection rate?--a pilot study. Am J Gastroenterol 
2008;103:1926-1932.
Chapter 2
34
 127.  Dove-Edwin I, Boks D, Goff S, Kenter GG, Carpenter R, et al. The outcome of endometrial 
carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal 
carcinoma and familial colorectal carcinoma. Cancer 2002;94:1708-1712.
 128.  Rijcken FE, Mourits MJ, Kleibeuker JH, Hollema H, van der Zee AG. Gynecologic screening in 
hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003;91:74-80.
 129.  Renkonen-Sinisalo L, Butzow R, Leminen A, Lehtovirta P, Mecklin JP, et al. Surveillance for endome-
trial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 2007;120:821-824.
 130.  Schmeler KM, Lu KH. Gynecologic cancers associated with Lynch syndrome/HNPCC. Clin Transl 
Oncol 2008;10:313-317.
 131.  Kwon JS, Sun CC, Peterson SK, White KG, Daniels MS, et al. Cost-effectiveness analysis of preven-
tion strategies for gynecologic cancers in Lynch syndrome. Cancer 2008;113:326-335.
 132.  Mecklin JP, Jarvinen H. Treatment and follow-up strategies in hereditary nonpolyposis colorectal 
carcinoma. Dis Colon Rectum 1993;36:927-929.
 133.  van Dalen R, Church J, McGannon E, Fay S, Burke C, et al. Patterns of surgery in patients belonging 
to amsterdam-positive families. Dis Colon Rectum 2003;46:617-620.
 134.  de Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P, Cats A, Menko FH, et al. Decision 
analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut 
2003;52:1752-1755.
 135.  Liang JT, Huang KC, Lai HS, Lee PH, Cheng YM, et al. High-frequency microsatellite instability 
predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage 
IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer 2002;101:519-525.
 136.  Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, et al. Tumor microsatellite-instability 
status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N 
Engl J Med 2003;349:247-257.
 137.  Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, et al. Use of 5-fluorouracil and survival 
in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004;126:394-401.
 138.  Fallik D, Borrini F, Boige V, Viguier J, Jacob S, et al. Microsatellite instability is a predictive fac-
tor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 
2003;63:5738-5744.
 139.  de Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH, Nagengast FM, Menko FH, et 
al. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis 
colorectal cancer. Int J Cancer 2004;109:468-471.
 140.  Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, et al. A randomized trial of aspirin to prevent 
colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-890.
 141.  Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, et al. A randomized trial of aspirin to prevent 
colorectal adenomas. N Engl J Med 2003;348:891-899.
 142.  Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, et al. Daily soluble aspirin and preven-
tion of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 
2003;125:328-336.
 143.  Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR. Aspirin and folic acid for the preven-
tion of recurrent colorectal adenomas. Gastroenterology 2008;134:29-38.
Chapter 3
Cancer risk in MLH1, MSH2 
and MSH6 mutation carriers; 
different risk profiles may 
influence clinical management
Dewkoemar Ramsoekh1,2, Anja Wagner3, Monique E. van Leerdam1, Dennis 
Dooijes3, Carli Tops4, Ewout W. Steyerberg2 and Ernst J. Kuipers1,5
Departments of 1Gastroenterology and Hepatology, 2Public Health, 3Clinical 
Genetics and 5Internal Medicine, Erasmus MC University Medical Center, 
Rotterdam, the Netherlands
4Department of Human and Clinical Genetics, Leiden University Medical 
Center, Leiden, the Netherlands
Submitted for publication
Chapter 3
36
AbSTRACT
background & Aims: Lynch syndrome (LS) is associated with a high risk for colorectal cancer 
(CRC) and extracolonic malignancies, such as endometrial carcinoma (EC). The risk is depen-
dent of the affected mismatch repair gene. The aim of the present study was to calculate the 
cumulative risk of LS related cancers in proven MLH1, MSH2 and MSH6 mutation carriers.
methods: The study population consisted out of 67 proven LS families. Clinical information 
including mutation status and tumour diagnosis was collected. Cumulative risks were calculated 
and compared using Kaplan Meier survival analysis. 
Results: MSH6 mutation carriers, both males and females had the lowest risk for developing 
CRC at age 70 years, 54% and 30% respectively and the age of onset was delayed by 3-5 years 
in males. With respect to endometrial carcinoma, female MSH6 mutation carriers had the highest 
risk at age 70 years (61%) compared to MLH1 (25%) and MSH2 (49%). Also, the age of EC 
onset was delayed by 5-10 years in comparison with MLH1 and MSH2. 
Conclusions: Although the cumulative lifetime risk of LS related cancer is similar, MLH1, 
MSH2 and MSH6 mutations seem to cause distinguishable cancer risk profiles. MSH6 mutation 
carriers have a low CRC risk under the age of 30. As a possible consequence, surveillance 
colonoscopy starting at a higher age is more suitable. 
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INTRODuCTION
Lynch syndrome (LS), also known as hereditary non-polyposis colorectal cancer, is the most 
common hereditary colorectal cancer (CRC) syndrome and accounts for 2-5% of all colorectal 
cancer cases.1 Germline mutations in any of the four mismatch repair (MMR) genes, MLH12, 
MSH23, MSH64 and PMS25, are the underlying cause of LS. Subjects carrying a mutation in one 
of the MMR genes have a higher risk for developing colorectal cancer, but also endometrial 
carcinoma and to a lesser extent malignancies of the stomach, small bowel, ovaries, upper 
uroepithelial tract, biliary tract, skin and brain are more often seen in these subjects.6-9
The colorectal cancer risk in LS is dependent on sex and the MMR gene involved. The reported 
lifetime risk for colorectal cancer in the literature varies from 28-100% in males and 25-83% in 
females.7, 10-18 The risk of developing endometrial carcinoma ranges from 30-71% and the risk of 
other LS-associated cancers is less than 10-15%.9 Furthermore, some studies have suggested that 
extracolonic cancers are more often observed in MSH2 mutation families compared to MLH1 
mutation families.13, 19 MSH6 mutation families probably have a milder clinical phenotype with 
a later onset of both CRC an EC and clustering of endometrial carcinoma.17 The risks in PMS2 
mutation families are largely unknown. One study reported that PMS mutation families have a 
milder phenotype compared to MLH1 or MSH2 mutation families.20
Unfortunately, the precise lifetime risk for CRC and endometrial carcinoma may be biased 
because the families selected in previous studies were mainly selected on basis of clustering of 
CRC or fulfilment of clinical criteria (Amsterdam II criteria). Furthermore, it was not always 
clear whether the affected subjects were proven mutation carriers. In addition, most studies have 
only evaluated lifetime risks for MLH1 and MSH2 mutations, while studies evaluating MSH6 
mutation families are sparse. The most efficient way to calculate the lifetime risks of CRC and 
EC in Lynch syndrome would be to calculate these risks based on a cohort of proven mutation 
carriers. Therefore, the aim of the present study was to calculate the cumulative lifetime risks 
for CRC and EC in Lynch syndrome using a cohort of proven MLH1, MSH2 and MSH6 mutation 
carriers.
mATERIALS AND mETHODS
Study population
During the period 1994-2007, an MMR gene mutation was detected in 67 families who were 
counselled at the Department of Clinical Genetics of the Erasmus MC University Medical 
Center, because of a clinical suspicion for Lynch syndrome. Clinical data of family members 
including sex, age, mutation status, age at diagnosis of both LS-associated and other cancers 
were collected. LS-associated cancer included colorectal, endometrial, stomach, ovaries, up-
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per uroepithelial tract, biliary tract, skin and brain cancer. Also, the site of the tumour, age at 
death and cause of death were collected. The cancer diagnosis was confirmed by pathology and 
medical reports. In addition, data regarding colonoscopic surveillance of affected and unaffected 
family members were collected.
Only subjects with a proven MMR gene mutation were included in this study.
mutation analysis
Mutation analysis was performed by denaturing gradient gel electrophoresis, sequencing and 
multiplex ligation-dependent probe amplification (MRC-Holland kits P003 and P008). Mutation 
nomenclature was used according to international guidelines (www.hgvs.org). A variant was 
considered a mutation when leading to a predicted truncated protein or based on previously 
published data. Silent or missense variants which were previously unreported or of unclear 
status were labelled unclassified variants (UV) and not considered as an MMR gene mutation.
Statistical analysis
Data were submitted for statistical testing using the Statistical Package for the Social Sciences 
(SPSS Inc, Chicago, IL), version 12.0.1. Data are given as median and range or as mean with 
standard deviation when appropriate. The chi square test, Student’s t test and log rank test were 
used to compare differences between MLH1, MSH2 and MSH6 mutation carriers. Penetrance for 
age was calculated using the Kaplan Meier survival analysis method and included the 67 index 
cases. In case of multiple or recurrent colorectal carcinoma or endometrial adenocarcinoma, 
only the first diagnosis of either cancer was included in the analysis. The observation time 
for the different cancers was from birth until the date of first cancer diagnosis, death, date of 
hysterectomy (only for the observation time of endometrial carcinoma) or the end of the study 
(31 December 2007). A p value below .05 was considered statistically significant.
RESuLTS
Study population
In the 67 families with an MMR gene mutation, 26 (39%) were detected with an MLH1 mutation, 
20 (30%) with an MSH2 mutation and 21 (31%) with an MSH6 mutation. Of the 67 families, 46 
(69%) met the Amsterdam II criteria. Mutation analysis was performed in 725 subjects (296 men 
and 429 women) and a mutation was identified in 246 subjects (92 men, 154 women) (Table 1). 
At the time of mutation analysis the mean age of the 246 mutation carriers was 49 (± 16) years.
39
Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management
Ch
ap
ter
 3
Of the 246 mutation carriers, 115 (47%) were diagnosed with a Lynch syndrome associated 
tumour. One hundred and four (42%) mutation carriers already had been diagnosed with a Lynch 
syndrome associated tumour before mutation analysis was performed. Colorectal cancer was 
diagnosed in 83 (34%) mutation carriers, including 17 (7%) mutation carriers who developed 2 
or more CRCs during their lifetime. Endometrial carcinoma was diagnosed in 37 (24%) of the 
154 female mutation carriers, including 13 mutation carriers who also developed CRC during 
their life. Of the six families with a strong family history of endometrial carcinoma (two or more 
cases within the family), five (83%) were diagnosed with an MSH6 mutation. With respect to the 
other LS-associated cancers, 19 (8%) mutation carriers developed another LS-associated cancer 
during their life (Table 1). Seven of these nineteen mutation carriers were also diagnosed with 
CRC, one mutation carrier also with endometrial carcinoma and four mutation carriers with both 
CRC and EC.
In total, 194 mutation carriers were under colonoscopic surveillance, including 69 subjects 
who had already been diagnosed with colorectal cancer before mutational testing was performed. 
One of these 69 mutation carriers was already diagnosed with endometrial carcinoma at the time 
of mutation analysis and developed colorectal cancer shortly after being one year under colono-
scopic surveillance. The other 68 mutation carriers were included in a colonoscopic surveillance 
program after being diagnosed with colorectal cancer. These 68 subjects were treated surgically 
(partial colectomy) for colorectal cancer and colonoscopic surveillance of the remaining colon 
was performed. Of the remaining 125 mutation carriers none developed colorectal cancer and 
in 23 (18%) adenomatous polyps had been detected and removed. The person-years of follow 
up was 1414 years and the mean follow up time of the subjects under colonoscopic surveillance 
was 7 ± 4 years. 
Table 1. Study population characteristics
MLH1 MSH2 MSH6 Total
Families 26 20 21 67
Mutation carriers 70 67 109 246
Males (%) 28 (40) 28 (42) 36 (33) 92 (37)
Subjects with colorectal cancer (%) 36 (51) 21 (31) 26 (24) 83 (34)
Subjects with endometrial carcinoma 7 (10) 9 (13) 21 (19) 37 (15)
Subjects with other Lynch associated cancer (%)* 
Ovarian carcinoma 1 (1) 3 (4) 6 (6) 10 (4)
Small bowel cancer 1 (1) 2 (3) 0 (0) 3 (1)
Transitional cell carcinoma 0 (0) 3 (4) 3 (3) 6 (2)
* No histological proven stomach cancers were reported.
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Lifetime risks
The respective lifetime risks curves are shown in figures 1-4. For all LS-associated tumours, the 
cumulative risks in both male and female mutation carriers at 70 years was 71% for MLH1, 77% 
for MSH2 and 75% for MSH6 mutation carriers (Figure 1). Although the cumulative risks at age 
70 years were similar for the three different MMR genes, the log rank test showed a significant 
difference for developing any Lynch syndrome associated cancer between MSH6, MLH1 and 
MSH2 mutation carriers (p = 0.01). This was due to the fact that before the age of 70 years the 
risk of developing any Lynch syndrome associated cancer in MSH6 carriers was lower compared 
to MLH1 or MSH2 mutation carriers (Figure 1). 
In Figure 2, the age related cumulative risk for CRC is shown for male MLH1, MSH2 and 
MSH6 mutation carriers. At age 70 years, the cumulative risk was the highest for MLH1 muta-
tion carriers, 78%, while the cumulative risks for MSH2 and MSH6 mutation carriers were 57% 
and 54% respectively. There was no significant difference in age related cumulative risk between 
MSH6 mutation carriers (p = 0.05) compared to MLH1 and MSH2 mutation carriers. However, 
the highest increase in risk in male MLH1 and MSH2 mutation carriers was observed between 
the ages of 40 to 50 years, while the risk in male MSH6 mutation carriers mostly increased 
Figure 1. All Lynch associated tumours: cumulative risks for MLH1, MSH2 and MSH6 mutation carriers.
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between the ages of 50 to 60 years. Although the age related risks were not significant different 
between the three different MMR genes, there was a trend in male MLH1 and MSH2 mutation 
carriers to develop CRC at an earlier age than male MSH6 mutation carriers. The cumulative 
risks for CRC in females were lower compared to males, 57% for MLH1, 52% for MSH2 and 
30% for MSH6 mutation carriers (Figure 3), with a significantly lower age related cumulative 
risk in MSH6 mutation carriers (p = 0.001) compared to MLH1 and MSH2 mutation carriers. 
For endometrial carcinoma, the highest cumulative risk was observed in the MSH6 mutation 
carriers (61%), while the cumulative risks for MLH1 and MSH2 mutation carriers were 25% 
and 49% respectively. However, the log rank test showed no significant difference in age related 
cumulative risk (p = 0.58) between MSH6 mutation carriers compared to MLH1 and MSH2 
mutation carriers.
median age of onset
The median age of CRC onset in males was significantly higher in MSH6 mutation carriers (48 
years; range 32-84 years) compared to MSH2 mutation carriers (43 years; range 20-51 years, 
p = 0.03), but not significantly higher compared to MLH1 mutation carriers (45 years; range 
33-63 years, p = 0.07). For female mutation carriers, no significant differences in the median 
age of CRC onset were found when comparing MSH6 (53 years; range 34-61 years) with MLH1 
(50 years; range 25-79 years, p = 0.88) and MSH2 (44 years; range 29-82 years, p = 0.28). The 
Figure 2. Colorectal cancer in males; cumulative risks for MLH1, MSH2 and MSH6 mutation carriers.
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median age of EC onset was significant higher in MSH6 mutation carriers (56 years; 47-67 
years) compared to MLH1 mutation carriers (51 years; 46-54 years, p = 0.02) and MSH2 muta-
tion carriers (46 years; 36-55 years, p = 0.001). There were no significant differences in the age 
of onset of other LS-associated cancers between MLH1 (53 years; range 52-54 years), MSH2 
(42 years; range 23-59 years) and MSH6 (50 years; range: 35-76) mutation carriers (MLH1 vs. 
MSH2, p = 0.41; MLH1 vs. MSH6, p =0.76 and MSH2 vs. MSH6, p = 0.41). 
Discussion
In this study, we evaluated 246 individuals from 67 families with a proven mismatch repair gene 
mutation to determine the cumulative lifetime risk of developing cancer. Previous studies have 
shown different lifetime risks for developing CRC in Lynch patients. 
One of the first studies evaluating the lifetime risk reported a lifetime risk for CRC at age 75 
years of 92% in males and 83% in females.10 Most later studies reported somewhat similar risks 
for CRC ranging from 65-100% in males and 30- 63% risk in females.7, 11-13 A more recently 
published study reported the lowest lifetime risk for CRC so far, 27% for males and 22% for 
females at age 70 years.15 All these studies only evaluated the risks associated with MLH1 and 
MSH2 mutations. Thirty one percent of the families included in our study carried an MSH6 
Figure 3. Colorectal cancer in females, cumulative risks for MLH1, MSH2 and MSH6 mutation carriers.
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mutation. This frequency is higher than previously reported.4, 21-23 Studies evaluating the lifetime 
risks of cancer amongst MLH1, MSH2 and MSH6 families are sparse. A study evaluating the risk 
in 20 MSH6 families showed that colorectal cancer was less frequent and developed 10 years 
later in MSH6 compared to MLH1 and MSH2. In addition a significant higher lifetime risk of 
endometrial carcinoma of 71% in MSH6 mutation carriers with a later age of onset (54 years 
vs. 48 and 49 years for MLH1 and MSH2) was reported.17 A German study comparing 27 MSH6 
mutation families with 156 MLH1 and MSH2 mutation families confirmed the lower risk and 
later age of onset of CRC in MSH6 families.24 These results were also confirmed by a recently 
published British study, but this study only included 11 proven MSH6 mutation carriers.18 
Our study indicates that, however the cumulative risks of cancer at age 70 years in MLH1, 
MSH2 and MSH6 mutation carriers is similar, each mutated gene has a distinguishable cancer 
risk profile. In MSH6 mutation carriers the risk at age 70 years for developing CRC was the 
lowest in both male (54%) and female (30%) when compared to carriers of MLH1 and MSH2 
mutations. Between male MSH6 and MSH2 mutation carriers also a significant difference in the 
age of CRC onset (48 vs. 43 years, p = 0.03) was found and there was a trend in higher age of 
CRC onset between male MSH6 and MLH1 mutation carriers. For female mutation carriers, no 
significant differences were found in the mean age of onset of CRC. This can be explained by 
the fact that female MLH1 and MSH2 mutation carriers still developed CRC at an older age. The 
Figure 4. Endometrial carcinoma in females, cumulative risks for MLH1, MSH2 and MSH6 mutation carriers.
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lower risk of CRC onset in female MSH6 mutation carriers under the age of 50 years raises the 
question whether colonoscopic surveillance guidelines in these subjects can be changed. Current 
guidelines advise to start with biennial colonoscopy surveillance from the age of 20-25 years.25 
In our study population, the youngest affected female MSH6 mutation carrier with CRC was 34 
years. Our data and the data from previous studies support that colonoscopic surveillance can be 
started at an age of 30 years in female MSH6 mutation carriers.17 
However our numbers are too small to draw definite conclusions, CRC seems to be the pre-
dominant cancer in MLH1 mutation carriers. In MSH2 and MSH6 mutation carriers extracolonic 
cancers appear to contribute more to the similar cumulative lifetime risk of cancer in MLH1, 
MSH2 and MSH6 mutation carriers. A higher risk of extracolonic-LS-associated cancer was 
previously reported in MSH2 mutation carriers compared to MLH1 mutation carriers.13, 19 Unfor-
tunately, the number of extracolonic-LS associated cancer (excluding endometrial carcinoma) 
in our study population was too low to calculate accurate risk estimates for these cancers. In 
concordance with other studies 17, 26 our study indicates that MSH6 carriers have the highest en-
dometrial cancer risk followed by MSH2 and MLH1 mutation carriers. Also, this risk increases 
sharply after the age of 50 years. In view of the disputable effect of endometrial carcinoma 
surveillance 27, 28, in female MSH6 carriers aged 45 years or above prophylactic hysterectomy 
may be suggested in order to decrease the risk for developing endometrial carcinoma.29 In MSH2 
and MLH1 female mutation carriers this option may be more questionable. In MSH2 muta-
tion carriers the risk of other extracolonic and extraendometrial cancers may reduce faith in 
and benefit of risk reducing surgery. In MLH1 mutation carriers the risk of endometrial cancer 
may not outweigh the disadvantages of surgery. In case of surgery for another cause, additional 
hysterectomy should be considered also in MLH1 en MSH2 mutation carriers. 
A strength of the present study was that the age related risks where calculated using proven 
mutation carriers. However, the age related risks might be somewhat lower since not all the 
unaffected individuals from proven mutation families opted for genetic testing and thus the total 
number of unaffected mutation carriers in the mutation families may be underestimated. 
In addition, individuals with a higher risk for mutation carriership, i.e. with an affected first 
degree relative, more often opt for genetic testing.30 This may also have introduced some bias 
with respect to the age related risks. Also, we included the index cases in our study population. 
Index cases give rise to the suspicion of Lynch syndrome and they always have cancer. This may 
also have resulted in a slightly higher age related risk. On the other hand, the majority (77%) of 
not affected mutation carriers was under colonoscopy surveillance, which likely has influenced 
the age related risks for developing invasive CRC, since colonoscopy surveillance in Lynch 
syndrome patients is effective in reducing the incidence and mortality of CRC.31 A limitation of 
our study was that our study population was not very large (n=246), and the number of male car-
riers was 92. This could explain why we did not find a significant difference in both the mean age 
of CRC onset and the age related risk between male MLH1, MSH2 and MSH6 mutation carriers.
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In conclusion, the present study indicates that, although the cumulative risks at age 70 years 
of LS related cancer in MLH1, MSH2 and MSH6 mutation carriers are similar, each mutated 
gene has a distinguishable cancer risk profile. It underlines that MSH6 mutation carriers have a 
distinct clinical phenotype with a lower CRC risk and a higher risk for developing endometrial 
carcinoma. Starting with biennial colonoscopic surveillance at an age of 30 years instead of 
an age of 20-25 years in female MSH6 mutation carriers is more suitable. Moreover, in female 
MSH6 mutation carriers prophylactic hysterectomy may be considered from an age of 45 years.
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AbSTRACT
background/aims: In Lynch syndrome, the clinical phenotype in MSH6 mutation families dif-
fers from that in MLH1 and MSH2 families. Therefore, MSH6 mutation families are less likely 
to fulfil diagnostic criteria such as the Amsterdam II criteria (AC II) and the revised Bethesda 
guidelines (rBG), and will be underdiagnosed. The aim of the present study was to evaluate the 
contribution of MSH6 gene mutations in families that were analysed for Lynch syndrome in a 
diagnostic setting.
methods: Families that had molecular analysis for Lynch syndrome were included in this study. 
Complete molecular screening of the MLH1, MSH2 and MSH6 genes was performed in all fami-
lies. Microsatellite instability (MSI) and immunohistochemical (IHC) analysis was performed 
in almost all families. Clinical data were collected from medical records and family pedigrees.
Results: A total of 108 families were included. MSI and IHC analysis was performed in 97 
families and in 40 an MSI-high phenotype with absent protein expression was found. Germline 
mutation analysis detected mutations in 23 families (7 MLH1, 4 MSH2 and 12 MSH6). The 
majority of MSH6 families were AC II negative, but fulfilled the rBG.
Conclusions: There is a high incidence of MSH6 mutations in families tested for Lynch syn-
drome in a diagnostic setting. Many of these families remain underdiagnosed using the AC II. 
The rBG are more useful to select these families for further analysis. However, to optimize the 
detection of MSH6 families, MSI and IHC analysis should also be performed in families with 
clustering of late onset endometrial carcinoma.
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INTRODuCTION
Lynch syndrome (LS), also known as hereditary non-polyposis colorectal cancer (HNPCC), 
is the most common form of hereditary colorectal cancer (CRC) and accounts for 2-5% of all 
CRC.1, 2 This syndrome is mainly characterized by early onset of CRC and endometrial carci-
noma. In addition, tumours of the stomach, small bowel, urinary tract, ovaries, brain and skin 
occur at higher frequencies in Lynch syndrome families compared to the general population.3 
Traditionally, LS is clinically defined by the diagnostic Amsterdam criteria, which were initially 
introduced in 1990 (AC-I).4 In 1999 these criteria were modified with the inclusion of the LS 
associated extracolonic tumours (AC-II, Table 1).5 In order to increase the identification of LS 
carriers the Bethesda guidelines were formulated and subsequently revised in 2004 into the 
revised Bethesda guidelines (rBG).6, 7 The rBG are used to identify tumours that should be tested 
for microsatellite instability (MSI) in order to select patients for further analysis of mismatch 
repair (MMR) gene mutations. Mutations in these genes (MLH1, MSH2, MSH6 and PMS2) 
underlie LS, but the phenotype may differ depending on the affected gene. In particular, the 
clinical phenotype of MSH6 mutation carriers seems to differ from MLH1 and MSH2 mutation 
carriers. These differences include a later age of onset of the tumours, a lower risk of CRC and 
a higher risk of endometrial carcinoma in female MSH6 mutation carriers.8, 9 Several reports 
showed that mutations in the MLH1 and MSH2 genes account for almost 90% of Lynch syn-
drome cases, while mutations in the MSH6 gene account for approximately 10% of cases. PMS2 
mutations have been reported in only a few families thus far.10-13 The aim of the present study 
was to evaluate the contribution of mutations in the MSH6 gene, in comparison to MLH1 and 
Table 1. The Amsterdam Criteria II and the revised Bethesda guidelines
Amsterdam Criteria II 
There should be at least three relatives with a LS associated tumour 
(CRC, endometrial, small bowel, ureter/renal pelvis cancer);
all of the following criteria should be present:
• one should be a first degree relative of the other two
• at least two successive generations should be affected
• at least one should be diagnosed before age 50 years
• all tumours should be verified by pathological examination
• FAP should be excluded in the CRC case
Revised Bethesda guidelines
• CRC diagnosed before age 50 years
• presence of synchronous / metachronous LS-related cancer*, regardless of age
• CRC with specific pathological features < 60 years**
• Patient with CRC with one or more 1st  degree relatives with an LS related cancer, with 1 of the diagnosis under age 50 years
• Patient with CRC with two or more 1st or 2nd degree relatives with an LS related cancer, regardless of age
* LS related cancer: CRC, endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, biliary tract, brain, sebaceous gland and small bowel 
carcinoma.
* *tumour infiltrating lymphocytes, Crohn’s-like lymphocyte reaction, mucinous/signet ring differentiation or medullary growth pattern.
Chapter 4
52
MSH2 mutations, in families that presented in a diagnostic setting with a familial clustering of 
CRC and other LS associated tumours. 
mETHODS
Study population
Following genetic counselling at the department of Clinical Genetics of the Erasmus MC Uni-
versity Medical Center, a total of 108 families were tested for germline mutations of the MMR 
genes during the period 2000-2006 because of a clinical suspicion of LS. 
Microsatellite instability (MSI) analysis and/or immunohistochemistry (IHC) analysis was 
performed in tumours originating from one or more index cases of these families. Mutation 
analysis of the MLH1, MSH2 and MSH6 genes was mostly performed in the youngest colorectal 
cancer or endometrial carcinoma patient in the family. The family pedigrees of the 108 families 
were evaluated for compliance to the AC II and rBG (Table 1).
Late onset colorectal cancer or endometrial cancer was defined as cancer diagnosed above the 
age of 50 years. Clinical data were collected from family pedigrees and medical records. The 
data collection included the diagnosis of cancer, the age at diagnosis, the presence of multiple 
(synchronous or metachronous) tumours, results of MSI and immunohistochemical (IHC) analy-
sis and the results of DNA mutation analysis.
molecular analyses
Microsatellite instability analysis
MSI analysis was performed on paired tumour and normal tissue DNA using a panel of 5 mic-
rosatellite markers (BAT 25, BAT 26, BAT 40, D2S123 and D5S346), as described previously.14 
Tumours were regarded MSI-high if at least two of the five markers showed instability, MSI-low 
if one of the five markers showed instability and MSI-stable if all markers were stable.
Immunohistochemical analysis
IHC analysis for MLH1, MSH2 and MSH6 was carried out by using the primary antibodies 
anti-MLH1, anti-MSH2 and anti-MSH6, as described previously.14 The sections were scored 
as either negative (i.e. the absence of detectable nuclear staining of cancer cells) or positive for 
MLH1, MSH2 and MSH6 staining.
53
A high incidence of MSH6 mutations in Amsterdam Criteria II negative families tested in a diagnostic setting
Ch
ap
ter
 4
BRAF mutation analysis
BRAF mutation analysis for the p.Val600Glu mutation (p.V600E) was performed to determine 
the presence of a sporadic CRC and to rule out Lynch syndrome in patients with MSI-positive 
tumours and absent MLH1 staining. Mutation analysis was performed by direct sequencing of 
tumour DNA, as described previously.15 
Germline mutation analysis
Genomic DNA from the index patients was isolated from peripheral blood samples. The analysed 
families were predominantly of Dutch ethnic background. All coding regions and intron-exon 
boundaries of the MLH1, MSH2 and MSH6 genes were completely analysed using direct se-
quence analysis (PCR primers and reaction conditions available on request). Reaction products 
were analysed using an ABI 3730xl capillary automated sequencer. In addition, all three genes 
were analysed for genomic rearrangements using Multiplex Ligation-dependent Probe Amplifi-
cation (MLPA kits P003 & P008, MRC Holland). Mutation nomenclature was used according to 
international guidelines (http://www.hgvs.org/mutnomen). In case of novel DNA variants, 200 
Dutch anonymous control chromosomes were screened to identify common polymorphisms. A 
variant was considered a mutation when leading to a predicted truncated protein or based on 
previously published data. Silent or missense variants, which were previously unreported or of 
unclear status were labelled unclassified variants (UVs).
Haplotype analysis in MSH6 mutation families
To identify possible founder effects underlying the presence of the c.1614_1615delCTinsAG 
and p.Ser156X mutations in the population extended haplotype analysis was performed. Sev-
eral intragenic polymorphisms and extragenic polymorphic markers flanking the MSH6 gene 
(D2S2298, D2S2240, D2S2378, D2S391, D2S288, D2S2227, AFM196XF6, AFM073WF3, 
AFM079XG9, D2S1248, D2S2156, D2S2251, D2S2153 and D2S378) were used to construct 
h aplotypes segregating with the c.1614_1615delCTinsAG mutation and the p.Ser156X muta-
tion in affected families. Intra familial segregation analysis was performed where possible, to 
confirm the validity of the constructed haplotypes.
Statistical analysis
Data were submitted for statistical testing by using the Statistical Package for the Social Sci-
ences (SPSS Inc, Chicago, IL), version 12.0.1. Data are given as median and range or as mean 
with standard deviation when appropriate. Chi square and student’s t test analysis was carried 
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out to evaluate differences between families. Sensitivity and specificity of the AC II and rBG 
were calculated. A two-sided p value less than 0.05 was considered significant.
RESuLTS
molecular analyses and germline mutation analysis
MSI and/or IHC analysis were performed in tumour tissue of 97/108 (90%) families (Figure 1) 
and an MSI-high phenotype was found in 40 (41%) of these families. Consecutive IHC analysis 
showed an absence of expression of at least one of the three MMR proteins in 37 of these 40 
families, including 22 families with an absence of MLH1 expression. BRAF p.V600E mutation 
analysis in these 22 families showed the presence of this mutation in 6 (27%) families. 
Germline mutation analysis for the MLH1, MSH2 and MSH6 genes was performed in all 108 
families. We detected 17 MMR mutations (5 MLH1, 4 MSH2 and 8 MSH6) in 94 families, in 
which both MSI and IHC analysis was performed. This included one MSH2 mutation in a family 
with an MSI-stable tumour and normal protein expression of the three MMR proteins. In two 
families, MSI analysis alone was performed and in both an MSI-stable phenotype was found. 
Germline mutation analysis did not detect a pathogenic mutation in these two families. In one 
family, MSI analysis failed, but consecutive IHC analysis showed an absence of MSH6 protein 
expression. Germline mutation analysis in this family resulted in the identification of an MSH6 
mutation.
In 11 families only germline mutation analysis was performed and in 5 of these families a 
mutation was identified (2 MLH1 and 3 MSH6). Taken together, a pathogenic MMR mutation 
was found in 23/108 families (7 MLH1, 4 MSH2 and 12 MSH6) (Tables 2 and 3).
Figure 1. Molecular screening and germline mutation analysis in 97 families.
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Performance of the Amsterdam II criteria and revised bethesda guidelines
Seventeen (16%) of the 108 families fulfilled the AC II criteria, including 9 (39%) with an MMR 
mutation (4 MLH1, 2 MSH2 and 3 MSH6)(Table 2). The sensitivity and specificity of the AC II 
for the detection of mutation families in this high-risk group was 39% and 91%, respectively. 
Seventy (65%) families, including 20 MMR mutation families, fulfilled the rBG, corresponding 
with a sensitivity and specificity of 87% and 41%, respectively, for the detection of mutation 
carriers. In three families that did not fulfil the rBG a pathogenic MMR mutation was identified. 
These families showed clustering of late onset CRC (one MLH1 family) or clustering of late 
onset endometrial carcinoma (2 MSH6 families). Of the 35 families that did not fulfil the rBG 
and in which no mutation was identified, 17 families showed clustering of late onset CRC and 
9 families showed clustering of other Lynch associated tumours. In the remaining 9 families 
there was one family member affected with late onset CRC in combination with the presence of 
adenomatous polyps in other family members. Combining the rBG with the presence of cluster-
ing of late onset CRC in a family would increase the sensitivity for detecting mutation carriers 
to 91%, but decrease the specificity to 21%. Combining the rBG with the presence of clustering 
of late onset endometrial carcinoma in the family would result in an increase of the sensitivity to 
96% and a small increase of specificity to 42%.
Characteristics of the mSH6 mutation families
Nine (75%) of the twelve MSH6 mutation families did not fulfil the AC II criteria, while 2 (17%) 
MSH6 mutation families did not fulfill the rBG. In these two families there was a clustering of 
late onset endometrial carcinoma. Seven (58%) of the 12 index cases from the MSH6 mutation 
families were diagnosed with endometrial carcinoma and three (25%) were diagnosed with 
colorectal cancer. Of the remaining two index cases, one was diagnosed with ovarian carcinoma 
Table 2. Family characteristics of the 108 families
Families No. Families AC II + rBG + No. CRC Mean age of 
CRC onset (yrs)
No. EC Mean age of  
EC onset (yrs)
Mutation
     MLH1 7 4 (57%) 6 (86%) 17 56 ± 11 4 45 ± 5
     MSH2 4 2 (50%) 4 (100%) 11 49 ± 21 2 52 ± 5
     MSH6 12 3 (25%) 10 (83%) 27 60 ± 14 19 57 ± 5
No Mutation 85 8 (9%) 50 (59%) 157 59 ± 14 9 62 ± 13
Total 108 17 (16%) 70 (65%) 212 58 ± 15 34 57 + 10
AC II = Amsterdam II criteria
rBG = revised Bethesda guidelines
CRC = colorectal carcinoma
EC = endometrial carcinoma
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and the other with uroepithelial carcinoma. In contrast to other reports, the mean age of CRC 
onset in the MSH6 families (60 ± 14 years) was not higher compared to the MLH1 mutation 
families (56 ± 11 years, p=0.3), the MSH2 mutation families (49 ± 21 years, p=0.07) or the non 
mutation families (59 ± 21 years, p=0.7). However, due to small numbers, this conclusion was 
not statistically significant. In our study, the mean age of endometrial carcinoma onset in the 
MSH6 families (57 ± 7 years) was significantly higher compared to the MLH1 mutation families 
(45 ± 5 years, p = 0.004), but not compared to the MSH2 mutation families (52 ± 5 years, p = 
0.29) or the non mutation families (62 ± 13 years, p=0.3).
The mSH6 mutations p.Ser156X and c.1614_1615delCTinsAG  are founder 
mutations 
In the families with a mutation in the MSH6 gene, two mutations were seen in more than one family 
(table 3). Analyses were performed to test whether the p.Ser156X and c.1614_1615delCTinsAG 
mutations showed a founder effect. Extended haplotype analysis was performed in probands of 
seven MSH6 mutation families with the p.Ser156X mutation. Five of these seven probands had 
been diagnosed with this MSH6 mutation elsewhere (Bonn, Germany and Leiden, the Nether-
lands). All seven p.Ser156X mutation carriers showed shared alleles from marker D2S391 to 
Table 3. Mutations in the MLH1, MSH2 and MSH6 genes that were identified during the study
Gene Exon Nucl. change Amino Acid Frequency Consequence No. of mutation carriers
MLH1 4 c.380G>A (p.Arg127Lys) 1 Splice donor site 1
6 deletion exon 6 1 Truncated/no protein 1
10 c.806C>G p.Ser269X 1 Nonsense 1
12 c.1039-2A>T 1 Splice acceptor site 1
12 c.1225C>T p.Gln409X 1 Nonsense 3
16 deletion exon 16 1 Truncated/no protein 2
16 c.1896G>A 1 Splice donor site 3
7
MSH2 2 c.212-1G>A 1 Splice acceptor site 1
3 c.551delT 1 Frameshift 1
5 c.942+3A>T 1 Splice donor site 6
13 c.2020G>C p.Gly674Arg 1 Missense 4
4
MSH6 3 c.476C>G p.Ser156X 4 Nonsense 20
4 c.651dupT 1 Frameshift 2
4 c.1614_1615delTCinsAG p.Tyr538X 3 Nonsense 17
4 c.1784delT 1 Frameshift 12
4 c.2719_2720delGT 1 Frameshift 9
6 c.3519_3522dup4 1 Frameshift 4
9 c.3932_3935dup4 1 Frameshift 2
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marker AFM079XG9, with a large number of recombination events in the regions outside the 
shared haplotype, indicating that the p.Ser156X is a founder mutation of ancient origin (Figure 
2a). Haplotype analysis in the probands of the three families with the c.1614_1615delCTinsAG 
mutation showed shared alleles from marker D2S2240 to marker D2S2153, demonstrating a 
founder effect for this MSH6 mutation too. 
Comparison of the c.1614_1615delCTinsAG haplotype with the haplotype of the similar 
c.1614_1615delCTinsG mutation showed that the c.1614_1615delCTinsAG mutation is on a 
different chromosomal background than the very similar c.1614_1615delCTinsG mutation (Fig-
ure 2b) and identifies the c. 1614_1615 dinucleotide in the MSH6 gene as a mutational hotspot. 
DISCuSSION
In this study we have evaluated the contribution of mutations in the MSH6 gene in families ana-
lysed for Lynch syndrome in a diagnostic setting and compared this with contributions of MLH1 
and MSH2 mutations. Twenty-three (21%) of the 108 analysed families carried a mutation in one 
of the mismatch repair genes, in particular in the MSH6 gene (52%). This finding is in contrast 
with previous studies, which reported that MSH6 gene mutations account for approximately 
10% of LS cases.10-13 There are a number of possible explanations for the high number of MSH6 
mutation families in our study population. 
Figure 2a. The haplotype associated with the p.Ser156X mutation as determined in 7 probands from independent families. The MSH6 
gene is between the dotted lines. Alleles of intragenic polymorphisms in the MSH6 gene are shown between the dotted lines. A schematic 
representation of alleles of extragenic polymorphic markers that were analysed are shown outside the dotted lines. All carriers of the p.Ser156X 
mutation shared alleles from marker D2S391 to marker AFM079XG9 (dark grey area). A large number of recombination events in the regions 
outside the shared haplotype (light gray) indicate an ancient origin of the p.Ser156X mutation. n.d.: not determined.
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Firstly, the MSH6 gene has been recognized as a cause of Lynch syndrome a few years later 
than the MLH1 and MSH2 genes.10, 16, 17 As a result, diagnostic MSH6 testing was implemented 
in laboratories a few years later and is still not routine analysis in all LS screening programs, 
causing an underdiagnosis of MSH6 families.
Secondly, previous studies may have underestimated the presence of MSH6 mutations due to 
the more atypical presentation of disease in MSH6 families 10, 18. As reported previously, MSH6 
mutations are associated with a lower colorectal cancer risk in combination with a later age of 
onset. Female MSH6 mutations carriers have a higher risk of developing endometrial carcinoma, 
but at a later age of onset than female MLH1 and MSH2 mutation carriers.8, 19 Clinicians may 
fail to recognize a positive family history of endometrial carcinoma as Lynch syndrome. Of 
all the endometrial carcinomas (n = 34) diagnosed in our study cohort, more than half were 
diagnosed in the twelve MSH6 families (n = 19). This supports previous findings suggesting a 
5-fold increased likelihood of finding a deleterious mutation in MSH6 among endometrial car-
cinoma patients compared to colorectal cancer patients.20, 21 Awareness of the high prevalence of 
endometrial carcinoma combined with the later onset of both CRC and endometrial carcinoma 
in MSH6 mutation families could result in an improved detection of MSH6 mutation families.
Thirdly, mutation analysis was performed in families presenting with clustering of Lynch 
syndrome associated tumours and not only restricted to AC II or rBG positive families. This may 
have resulted in a higher detection rate of MSH6 families. In our study population, the sensitivity 
of the AC II criteria was 39%. These findings are in line with previous studies which reported a 
sensitivity of 40% of the AC II criteria for the detection of MMR mutations.22-28 
Figure 2b. The haplotype associated with the c.1614_1615delTCinsAG mutation as determined in probands from 3 different families. 
The MSH6 gene is between the dotted lines. Alleles of intragenic polymorphisms in the MSH6 gene are shown between the dotted lines. A 
schematic representation of alleles of extragenic polymorphic markers that were analysed are shown outside the dotted lines. All carriers of 
the c.1614_1615delTCinsAG mutation shared alleles from marker D2S2240 to marker D2S2153 (dark grey area). The c.1614_1615delTCinsAG 
mutation is on a different chromosomal background than the similar c.1614_1615delTCinsG mutation (see haplotype 4), indicating a different 
origin and defining the c.1614_1615 position in the MSH6 gene as a mutational “hotspot”
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The reported sensitivity of the rBG is 90% and a similar sensitivity of 87% was found in 
our study.22-28 The MSH6 mutation families missed by the rBG showed only clustering of late 
onset endometrial carcinoma.29 Combining the rBG with the presence of clustering of late onset 
CRC showed an increase in the sensitivity to 91%. Also, to increase the detection of mutation 
families, combining the rBG with the clustering of late onset endometrial carcinoma might be an 
option. In our study, we found that this combination resulted in an increase of sensitivity to 96%. 
In seven of the twelve (58%) MSH6 mutation families a pathogenic founder mutation (p.Ser156X 
or c.1614_1615delCTinsAG ) was detected. A founder mutation arises in the DNA of an indi-
vidual who is a founder of a distinct population. Such a mutation can subsequently get passed 
on to next generations if it does not pose a great burden on reproductive fitness. Typically, the 
incidence of founder mutations can be increased at population bottlenecks. The identification 
of two founder mutations in the MSH6 gene during the present study suggests that the MSH6 
gene may accommodate founder mutations easily, possibly due to the fact that mutations in this 
gene cause a later onset of disease and thus form a smaller reproductive burden. This would also 
suggest that likely more MSH6 founder effects are out in the population waiting to be identified.
Theoretically, the presence of founder mutations may have influenced the high number of 
MSH6 families in our study population. In relatively small, homogenous and isolated popula-
tions the incidence of founder mutations may increase or at least remain stable because of the 
small effects of genetic drift. However, the Dutch population is not known to be a genetic isolate. 
Furthermore, data on the incidence of the contribution of MSH6 mutations in similar clinical 
patient groups in other populations is lacking, making this possibility difficult to address. Thus, 
it is presently not clear whether the high incidence of MSH6 mutations in our region can partially 
be explained by the presence of two founder mutations or whether it reflects the fact that the use 
of very stringent inclusion criteria for MSH6 mutation analysis in other studies (AC II) resulted 
in a failure to detect the majority of MSH6 families. 
A limitation of our study was the use of a selected clinical population consisting of families 
referred for genetic counselling of Lynch syndrome. All families were counselled and mutation 
analysis was performed at our clinical genetics department during a period of 7 years. Using 
such a clinical population will likely have introduced some selection bias. However, based on 
the large difference in the incidence of MSH6 mutations, we think that the previously reported 
incidence of 10% MSH6 mutations is an underestimation.
In conclusion, the present study reports a high number of MSH6 mutations, in families tested for 
Lynch syndrome in a diagnostic setting. The revised Bethesda guidelines identify the majority of 
MSH6 families. However, also in Bethesda negative families presenting with clustering of late 
onset endometrial carcinoma, MSI and IHC analysis should be performed.
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AbSTRACT
background/aims: The identification of Lynch syndrome is hampered by the absence of 
specific diagnostic features and underutilization of genetic testing. Prediction models have 
therefore been developed, but they have not been validated for a clinical genetic setting. The 
aim of the present study was to evaluate the usefulness of currently available prediction models. 
methods: We collected data of 321 index probands who were referred to the department of 
Clinical Genetics of the Erasmus Medical Center because of a family history of colorectal can-
cer. These data were used as input for five previously published models. External validity was 
assessed by discriminative ability (AUC: area under the receiver operating characteristic curve) 
and calibration. For further insight, predicted probabilities were categorized with cut-offs of 5%, 
10%, 20% and 40%. Furthermore, costs of different testing strategies were related to the number 
of extra detected mutation carriers.
Results: Of the 321 index probands, 66 harboured a germline mutation. All models discrimi-
nated well between high risk and low risk index probands (AUC: 0.82-0.84). Calibration was 
well for the Premm1,2 and Edinburgh model, but poor for the other models. Cut-offs could be 
found for the prediction models where costs could be saved while missing only few mutations. 
Conclusions: The Edinburgh and Premm1,2 model were the models with the best performance 
for an intermediate to high-risk setting. These models may well be of use in clinical practice to 
select patients for further testing of mismatch repair gene mutations.
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INTRODuCTION
Lynch syndrome, also known as hereditary non-polyposis colorectal cancer, is the most common 
form of hereditary colorectal cancer (CRC). This syndrome is characterized by early onset of 
CRC and endometrial cancer. In addition, tumours of the stomach, small bowel, urinary tract, 
ovaries, brain and skin occur at higher frequencies in Lynch syndrome families compared to the 
general population.1, 2 Lynch syndrome is caused by mutations in the mismatch repair (MMR) 
genes (MLH1, MSH2, MSH6 and PMS2). As a consequence, Lynch syndrome-associated tu-
mours exhibit microsatellite instability (MSI) and absent protein expression of the affected gene. 
Early identification of mutation carriers is important because of the high risk for colorectal 
cancer and other malignancies. 
Identification of mutation carriers can be based on a combination of clinical diagnostic 
criteria, the Amsterdam II criteria (AC II) and the revised Bethesda guidelines (BG).3, 4 The 
AC II, however, have a limited sensitivity for the detection of mutation carriers and therefore 
it is suboptimal for identification of mutation carriers. The BG were therefore developed to 
identify individuals eligible for molecular screening by microsatellite instability (MSI) and im-
munohistochemical (IHC) staining of MMR proteins. However, some components of the BG are 
rather complex. Molecular screening by MSI testing and IHC staining of proteins has a higher 
sensitivity compared to the AC II and BG 5-11 but MSI with absent staining of MLH1 and PMS2 
is also present in 15% of sporadic CRC cases.12-14 Furthermore, MSI and IHC analysis can only 
be performed when tumour tissue is available. The optimal diagnostic strategy for Lynch syn-
drome is still under debate. Performing MSI and IHC in CRC cases selected by the pathologists 
has been proposed as a diagnostic strategy by some authors9, 15, 16, while others propose fulfilment 
of BG followed by MSI and IHC analysis as a more effective strategy.10 These different views 
emphasize the need for other diagnostic tools in the identification of Lynch syndrome. In recent 
years, several models have been developed to predict the likelihood of carrying a germline muta-
tion.11, 17-20 These models use information from personal and family history as input to predict the 
probability of mutation carriership. A major advantage of prediction models is that these models 
give a quantitative estimate instead of a binary (yes/no) assessment as provided by the clinical 
diagnostic criteria. Mutation prediction models are thus potentially useful in clinical practice to 
optimise the identification of Lynch syndrome carriers, but the performances of these models 
have not been evaluated other than in similar settings as where they were developed. External 
validation is necessary to study generalizability of these models. Moreover, we need to consider 
the cut-off that should be used to select patients for further evaluation for Lynch syndrome. For 
example, a cut-off of 5% may be preferable to 10% if the additional costs of testing patients with 
risks between 5% and 10% are reasonable compared to the detection of some extra mutation 
carriers in this group. The aim of the present study was to evaluate the usefulness of five easily 
applicable mutation prediction models in a clinical population of familial CRC.
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methods
Study population
Since 1992 high-risk families for Lynch syndrome have been referred by general practitioners 
and medical specialists to the department of Clinical Genetics of the Erasmus MC University 
Medical Center for oncogenetic counselling. We included families with one or more subjects 
who had undergone cancer risk assessment for Lynch syndrome. From every family one or 
more family members underwent tumour analysis by MSI and IHC analysis, and /or underwent 
germline mutation analysis for mutations in the MLH1, MSH2 and MSH6 genes. In total, 321 
unrelated families with 17552 members were included in this study. In every family, an index 
proband was identified, defined as the youngest family member diagnosed with CRC and in 
which MSI, IHC analysis and/or germline mutation analysis had been performed. Demographic, 
clinical and tumour related characteristics of the index proband and a detailed family history 
were obtained from medical records and family pedigrees. Only findings that were confirmed 
by pathology or medical records were included. Family pedigrees were traced backwards and 
laterally as far as possible, at least to second-degree relatives. For all the affected individuals the 
age of cancer onset, type, location, tumour stage of the malignancy, the presence and number of 
colorectal adenomas and results of MSI, IHC and/or germline mutation analysis were recorded. 
Furthermore, the presence and number of colorectal adenomas and the results of germline muta-
tion analysis in healthy individuals was recorded.
molecular screening
MSI analysis was performed on paired tumour and normal tissue DNA using a panel of 5 vali-
dated microsatellite markers, as described previously.21 Tumours were regarded as MSI-high if 
at least two of the five markers showed instability, MSI-low if one of the five markers showed 
instability and MSI-stable if none of the markers showed instability.
Immunostaining for MLH1, MSH2 and MSH6 was carried out as described previously.21 The 
slides were scored as either negative (i.e. the absence of detectable nuclear staining of cancer 
cells), or positive for MLH1, MSH2 and MSH6 staining. Individuals found to have tumours 
with either an MSI-high phenotype or lack of MLH1, MSH2 or MSH6 protein expression were 
considered MMR deficient, while individuals with a tumour exhibiting an MSI-stable phenotype 
with normal MLH1, MSH2 or MSH6 protein expression were considered MMR proficient.
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Germline mutation analysis
All individuals with a MMR deficient tumour underwent germline mutation analysis of the 
MLH1, MSH2 and MSH6 gene. Germline mutation analysis was performed by sequencing and 
Multiplex Ligation-dependent Probe Amplification (MRC Holland). 
Classification of index probands
Index probands were considered positive if germline mutation analysis revealed a mutation in 
one of the mismatch repair genes. Index probands in whom germline mutation analysis detected 
an unclassified variant or no mutation were classified as non-mutation carrier. Index probands 
in which only MSI and IHC analysis had been performed and the analysis showed a MMR 
proficient tumour were also classified as non-mutation carrier.
Prediction models
Mutation probability estimates for MLH1, MSH2 and MSH6 were calculated using five, previ-
ously published prediction models, i.e. the Leiden11, PREMM1,219, Edinburgh18, UK-Amsterdam 
Plus (UK-Ams)17, and UK-Alternative (UK-Alt) model.17 The Leiden and PREMM1,2 model pre-
dict the likelihood of finding an MLH1 or MSH2 gene mutation, while the Edinburgh, UK-Ams 
and UK-Alt model predict the likelihood of finding a MLH1, MSH2 or MSH6 gene mutation in 
high risk individuals (Table 1). 
Cost effectiveness analysis
We estimated the costs and effects (number of detected mutations) of different diagnostic strate-
gies. The costs of tumour MMR deficiency (MSI and IHC) testing were estimated as € 590, 
the tariff recommended by the Dutch Pathology association (www.pathology.nl). The costs of 
germline mutation analysis were assumed to be  € 620 for each MMR gene.22 In case of direct 
germline mutation analysis, three MMR genes have to be analysed, thus the costs associated 
with this strategy was € 1,860. Tumour MMR deficiency analysis is mostly indicative for the 
mutated MMR gene and therefore the costs of subsequent germline mutation analysis was cal-
culated for a single MMR gene (€ 620). Costs were related to the number of mutations detected 
in MLH1, MSH2, or MSH6 genes for all prediction models. The diagnostic strategies included: 
i) direct germline mutation analysis in all index probands, ii) tumour MMR deficiency analysis 
in all index probands followed by germline mutation analysis in those with MMR deficient 
tumours and iii) a strategy in which prediction models were used to select cases eligible for ad-
ditional tumour MMR deficiency analysis and subsequent germline mutation analysis. Strategy 
iii considered consecutive cut-off values for the predicted probability of a mutation of each 
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prediction model, such that incremental cost-effectiveness could be calculated, expressed as 
extra costs (k€ = thousands of Euro) per extra detected mutation.
Statistical analysis
Sensitivity and specificity were calculated for the five different models with respect to the presence 
of a MLH1, MSH2, or MSH6 germline mutation, considering cut-offs for the predicted probability 
of a mutation of 5%, 10%, 20% and 40%. The predicted probabilities for each index proband 
included in the study were calculated using an extensive coding program in the SPSS software 
package (version 12.0.1, SPSS Inc, Chicago, IL), with verification in an independently developed 
Table 1. Input variables and features of the five prediction models.
Variable Leiden Premm1,2 Edinburgh UK-Ams UK-Alt
Model input
Gender counselee x
CRC status counselee x x x x x
CRC status relatives x x x x x
No. of CRC in counselee x x x
No. of relatives with CRC x x x
CRC age of onset counselee x x x x x
CRC age of onset relatives x x x x x
EC status counselee x x x x x
EC status relatives x x x x x
No. of relatives with EC x x x
EC age of onset counselee x x x
EC age of onset relatives x x x
Colonic adenoma status counselee x x† x†
Colonic adenoma status relatives x† x†
No. of relatives with colonic adenoma x†  
 x†
Lynch syndrome associated cancer status
counselee x
Lynch syndrome associated cancer status
relatives x
Fulfilment of Amsterdam II criteria x x
Presence of syn- / metachronous cancer x x‡ x‡
Proximal location CRC x
Model output
Predictions for carrying a MLH1 or MSH2 mutation x x
Predictions for carrying a MLH1, MSH2 or MSH6 x x x
CRC = colorectal cancer
EC = endometrial carcinoma
† For the UK-Ams and UK-Alt only counselees and relatives with > 5 colonic adenomas are included.
‡ For the UK-Ams and UK-Alt only individuals with syn- / metachronous CRC and EC are included.
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Microsoft Excel spreadsheet (Microsoft Corporation, Redmond, WA). The performance of the 
models was assessed with respect to discrimination and calibration. Discrimination is the model’s 
ability to separate patients with and without mutations. To quantify discrimination, the area under 
the receiver operating characteristic curve (AUC) was calculated. A model with an AUC of 0.50 
has no discriminative power, while an AUC of 1.0 reflects perfect discrimination. Calibration 
reflects the ability of a model to produce unbiased estimates of the probability of an outcome. For 
example, if patients with certain characteristics are predicted to have a 10% chance of carrying a 
mutation, the observed prevalence of mutation carriership should also be 10%. Calibration was 
assessed graphically by plotting observed outcome against the predicted probability (0%-100%). 
Calibration was further tested with the Hosmer-Lemeshow goodness-of-fit test.23 For the five mod-
els we compared observed outcome vs. predicted risks for each decile. Discrimination and calibra-
tion were calculated using R software (Version 2.5.1, the R Foundation for Statistical Computing). 
All p-values were two sided and a p-value of less than 0.05 was considered statistically significant.
RESuLTS
Index proband characteristics
A total of 321 unrelated index probands (155 male / 166 female) of 321 families were included 
in this study (Table 2). Twenty-seven (8%) and 155 (48%) of them met the Amsterdam II criteria 
and Bethesda guidelines respectively. Among the MLH1 and MSH2 mutation carriers, the BG 
were positive in respectively 84% and 91%. Among the MSH6 mutation carriers, the BG were 
positive in only 50%. The index probands were primarily analysed by MSI and IHC (n=277; 
86%) or by direct germline mutation analysis (n=44; 14%). Of the 277 (86%) index probands 
who underwent molecular analysis by MSI and IHC, 54 (19%) index probands had a tumour 
demonstrating MMR deficiency. Germline mutation analysis was performed in 175 (55%) index 
probands, 54 (31%) with an MMR deficient tumour, 77(44%) with an MMR proficient tumour 
and 44 (25%) who directly underwent germline mutation analysis. In total, 66 mutations in 
either MLH1 (n=25; 38%), MSH2 (n = 23; 35%) or MSH6 (n= 18; 27%) were identified. In 
146 (45%) index probands only MSI and IHC analysis was performed which showed an MMR 
proficient tumour. These index probands were considered as non-mutation carriers.
Detection of mutations
The AC II had a sensitivity for identification of mutation carriers of 30% (20/66) and a specific-
ity of 89% (228/255). The BG missed 15 of the 66 mutation carriers, corresponding with a 
sensitivity of 77% and a specificity of 59% (151/255). Molecular analysis with MSI and IHC 
in tumours of 277 index probands identified 54 (19%) index probands with a MMR deficient 
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tumour, corresponding with a sensitivity of 100% and a specificity of 89% for detection of 
mutation carriers.
Performance of prediction models
All prediction models discriminated well between high risk and low risk probands, with an 
AUC of 0.82 for the UK-Ams and UK-Alt model and an AUC of 0.84 for the Leiden, Premm1,2 
and Edinburgh model. Calibration curves showed considerable differences between observed 
mutation frequency and predictions from the Leiden, UK-Ams and UK-Alt models (Figure 1, 
Hosmer-Lemeshow goodness of fit test p < 0.0001). For example, the calibration curve in the 
Leiden model was above the dotted ideal line. This implies that most predicted probabilities for 
mutation carriership were systematically too low; for example index probands with a predicted 
probability of 40% actually had an observed probability for a mutation carriership around 70%. 
Table 2. Family history and index probands characteristics (n=321)
Characteristics MLH1 
mutation
MSH2 
mutation
MSH6 
mutation
No mutation Total
n (%) n (%) n (%) n (%) n (%)
Mutation status 25 23 18 255 321 
Family history
No. of CRC 65 64 41 426 596 
No. of EC 13 13 23 5 54 
No. of other LS-associated cancer 7 16 6 63 92 
Amsterdam II criteria +* 7 (28) 9 (39) 4 (22) 7 (3) 27 (8)
Revised Bethesda guidelines +* 21(84) 21 (91) 9 (50) 104 (41) 155 (48)
Proband characteristics
Male gender 11 (44) 10 (43) 8 (44) 126 (49) 155 (48)
Mean age CRC onset (yrs ± SD ) 44 (± 11) 30 (± 11) 52 (± 14) 54 (±13) 51 (± 13)
Mean age EC onset (yrs ± SD) 51 (± 4) 49 (± 4) 57 (± 5) 52 (± 5) 53 (± 6)
Site of tumour
        Proximal 22 (88) 16 (70) 10 (56) 66 (26) 114 (36)
Synchronous CRC 4 (16) 6 (26) 1 (6) 9 (4) 20 (6)
First degree relative with CRC
0 relatives 11 (44) 11 (48) 10 (56) 161 (63) 193 (60)
1 relative 8 (32) 8 (35) 5 (28) 81 (32) 102 (32)
≥ 2 relatives 6 (24) 4 (17) 3 (16) 13 (5) 26 (8)
MMR deficient tumour† 9/9 7/7 11/11 27/250 54/277
CRC = colorectal cancer
EC = endometrial cancer
LS = Lynch syndrome
SD = standard deviation
* fulfilling the Amsterdam II criteria or the revised Bethesda guidelines
† defined as MSI-high phenotype or loss of MLH1, MSH2 or MSH6 protein expression by immunohistochemistry
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Figure 1. Validation of the five mutation prediction models. 
The smooth curves reflect the relationship between observed fraction with a mutation and predictions from each model. Perfect calibration 
is represented by the straight dotted line through the origin. Triangles indicate the fraction of mutations in quintiles of patients with similar 
predictions, with 95% confidence intervals. Spikes at the bottom of each graph represent the distribution of predictions for those with and 
without mutations respectively.
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Using a probability cut-off value of ≥ 5%, the UK-Alt model identified all mutation carriers, 
corresponding with a sensitivity of 100% (Table 3). The 100% sensitivity of the UK-Alt model 
is explained by the fact that the predicted probabilities were systematically too high, as shown 
in Figure 1. The two well-calibrated models, the Premm1,2 and Edinburgh, both had a sensitiv-
ity of 98% at a 5% cut-off. The specificity of both models at a 5% cut-off was 22% and 9%, 
respectively. The Leiden model had the lowest sensitivity at a 5% cut-off (73%) and the highest 
specificity (80%), which relates to systematic underestimation of actual frequencies of muta-
Table 3. Performance characteristics of the prediction models according to different strategies 
Model Without MMR
deficiency analysis
With MMR 
deficiency analysis*
Sensitivity (%) Specificity (%) Specificity (%)
Leiden model
≥ 5% 73 80 80
≥ 10% 58 90 89
≥ 20% 38 98 100
≥ 40% 27 99 100
Premm1,2 model
≥ 5% 98 22 82
≥ 10% 88 67 87
≥ 20% 67 84 86
≥ 40% 29 94 87
Edinburgh model
≥ 5% 98 9 90
≥ 10% 94 29 90
≥ 20% 83 69 90
≥ 40% 53 96 89
UK-Ams model
≥ 5% 82 55 89
≥ 10% 76 80 84
≥ 20% 56 95 93
≥ 40% 38 99 100
UK-Alt model
≥ 5% 100 13 90
≥ 10% 91 24 91
≥ 20% 77 60 89
≥ 40% 65 91 87
* The sensitivity was calculated for 66 mutation carriers; specificity without MMR deficiency analysis for 255 index probands without mutation. 
The specificity with MMR deficiency analysis was calculated for 250 index probands without mutation among the 277 index probands who 
underwent tumour MMR deficiency analysis.
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tions (Fig 1). Using cut-off values of 10% or above resulted in a progressive loss of sensitivity 
of all the models (Table 3).
As expected, the combination of prediction models with subsequent MMR deficiency analysis 
before MMR mutation testing increased the specificity associated with each model. For example, 
at a 5% cut-off the specificity of the Premm1,2 model increased from 22% to 82%.
Cost effectiveness of different diagnostic strategies
The most expensive diagnostic strategy was direct germline mutation analysis in all index 
probands (k€ 597 or k€ 9,1 per mutation). Performing tumour MMR deficiency analysis in 
all index probands followed by germline mutation analysis in those with a MMR deficient 
tumour was less expensive (k€ 248, k€ 3,8 per mutation, Table 4). Using prediction models to 
select cases for additional tumour MMR deficiency analysis and subsequent germline mutation 
analysis was associated with lower costs, at the expense of missing mutations. At a 5% cut-off, 
the Leiden model was associated with the lowest costs (k€ 84), but 23 mutations would be 
missed. To detect all mutations, the extra costs per extra detected mutation were k€ 7. The 
Edinburgh and Premm1,2 models detected nearly all mutations at a 5% cut-off (65/66 and 64/66 
respectively). To detect the one or two missed mutations would cost an additional k€ 16 or k€ 
20 respectively. With a cut-off of 10%, three (65-62) or 11 (64-53) more mutations would be 
missed. The extra costs were k€ 37 and k€ 8 per extra mutation for the Edinburgh and Premm1,2 
model respectively. A cut-off of 20% would lead to many more mutations missed (62-55 = 7 and 
53-41 = 12 respectively), with costs of k€ 11 and k€ 4 per extra detected mutation. A cut-off 
of 5% for the Premm1,2 model hence had a similar cost-effectiveness as a threshold of 10% for 
the Edinburgh model, which is related to the slight difference in calibration at low predicted 
probabilities (Figure 1). Accepting a threshold for the costs per extra detected mutation of ap-
proximately k€ 10, would result in the use of different cut-off values. The Leiden and UK-Ams 
model should be used with a cut-off value less than 5%, the UK-Alt and Premm1,2 model with a 
≥ 5% cut-off and the Edinburgh model with a cut-off value of ≥ 10%
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DISCuSSION
Identification of high-risk subjects  at high risk for Lynch syndrome still remains difficult. In this 
study we found adequate discriminative ability of five different mutation prediction models for 
Lynch syndrome using clinical data of 321 index probands with suspicion of Lynch syndrome. 
Table 4. Cost effectiveness of the prediction models at different cut-off values.
MMR deficiency 
analysis (n)
Germline 
mutation 
analysis (n)
Total costs Mutations 
detected
(n)
Costs per 
extra detected 
mutation
MMR deficiency 
analysis
321 94 € 247,670 66 NA
Leiden model
≥ 0% 321 94 € 247,670 66 € 7,112
≥ 5% 90 50 €   84,100 43 € 2,871
≥ 10% 55 37 €   55,390 33 € 2,351
≥ 20% 24 21 €   27,180 21 € 1,505
≥ 40% 15 15 €   18,150 15 € 1,210
Premm1,2 model
≥ 0% 321 94 € 247,670 66 € 20,475
≥ 5% 260 86 € 206,720 64 €   8,331
≥ 10% 132 60 € 115,080 53 €   3,831
≥ 20% 73 42 €   69,110 41 €   1,724
≥ 40% 31 18 €   29,450 18 €   1,636
Edinburgh model
≥ 0% 321 94 € 247,670 66 € 16,640
≥ 5% 297 90 € 231,030 65 € 37,410
≥ 10% 242 82 € 193,620 62 € 10,524
≥ 20% 135 65 € 119,950 55 €   3,554
≥ 40% 45 36 €   48,870 35 €   1,396
UK-Ams model
≥ 0% 321 94 € 247,670 66 €   8,819
≥ 5% 170 67 € 141,840 54 € 11,270
≥ 10% 102 59 €   96,760 50 €   3,316
≥ 20% 51 38 €   53,650 37 €   1,852
≥ 40% 27 25 €   31,430 25 €   1,257
UK-Alt model
≥ 0% 321 94 € 247,670 66 ∞
≥ 5% 288 89 € 225,100 66 € 4,372
≥ 10% 253 80 € 198,870 60 € 7,796
≥ 20% 153 62 € 128,710 51 € 7,656
≥ 40% 66 46 €   67,460 43 € 1,569
NA = not applicable
75
Mutation prediction models in Lynch syndrome: evaluation in a clinical genetic setting
Ch
ap
ter
 5
Among the five models considered, the Premm1,2 and Edinburgh model had the best performance 
in predicting mutation carriership, because these two models had the highest discriminative 
ability and were well calibrated. Combining prediction models with tumour MMR deficiency 
analysis resulted in a substantial increase of the specificity. 
The calibration of the Leiden, UK-Ams and UK-Alt models was relatively poor, reflecting that 
predicted probabilities were systematically too high or too low. Although the Edinburgh model 
was developed using population-based data, this model was well calibrated in our intermediate 
to high-risk population. The Premm1,2 model and the Leiden model were designed to predict only 
the presence of MLH1 and MSH2 mutations. Recently, the Premm1,2 model was evaluated in a 
population based cohort of 1222 colorectal cancer patients, and identified all MLH1 and MSH2 
mutation carriers.24 However, the number of identified mutations (n=8) was very low, limiting 
the strength of the conclusions from this study.
In subjects suspected of Lynch syndrome, high sensitivity is important to identify mutation car-
riers. Tumour MMR testing in all by definition has the highest sensitivity (100%), but the lowest 
specificity (0%). This strategy was associated with high costs. Therefore, selection of high-risk 
individuals may be considered. The low sensitivity of the AC II and the complexity of the BG 
necessitate new diagnostic strategies to identify individuals at risk for Lynch syndrome. Predic-
tion models have a higher sensitivity compared to the AC II and BG if relatively low cut-offs 
are used for the predicted probability of mutation. With cut-offs of 5% to 10% such models can 
well be useful in a clinical setting. External validation showed that especially the Premm1,2 and 
Edinburgh model were accurate in predicting mutation carriership, with a sensitivity of 98% at 
a 5% cut-off. In clinical practice, these two models can be used to identify high-risk individuals 
who are eligible for tumour MMR deficiency analysis. Using prediction models led to lower 
costs than tumour MMR deficiency analysis in all CRC cases at the expensive of missing no or 
only few mutation carriers. The cost-effectiveness is determined by the cut-off value used, with 
lower cut-off values resulting in higher costs per extra detected mutation. The optimal threshold 
in terms of cost-effectiveness is not known and may depend on the specific health care setting. 
One might accept high costs per extra detected mutations when proven mutation carriers will 
follow colonoscopic surveillance. Such surveillance is highly effective in Lynch syndrome. A 
25-year-old person would gain 13.5 years of life expectance compared to no surveillance.25, 26 
The reported compliance in mutation carriers is approximately 90%, thus the expected gain 
in life expectancy may be only slightly less.27 Further establishment of the optimal threshold 
in terms of cost effectiveness and life years gained is needed. We note that the availability 
of user-friendly formats, such as the web-based Premm1,2 model (http://www.dana-farber.org/
pat/cancer/gastrointestinal/crc-calculator/), enables easy calculation of predicted probabilities 
in clinical practice. 
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Our study population consisted of families that had been counselled at the department of clini-
cal genetics. This enabled verification of the family history by medical records and pathology 
reports. The family history was as complete as possible which can be considered as strength of 
our study. But the results of this study may not apply to the performance of mutation prediction 
models in the general population, because we used an intermediate to high-risk study popula-
tion. Another limitation of our study was that not all probands underwent germline mutation 
analysis. We classified the probands with normal tumor MMR results and in whom no germline 
mutation analysis was performed as non-mutation carriers. Theoretically, these probands could 
harbour a mutation. However, the reported sensitivity of both MSI (80%-100%) and IHC analy-
sis (85-95%) are high.8-10, 18, 28-30 Finally, we only evaluated logistic regression based prediction 
models and therefore excluded the MMRpro model. MMRpro is a Mendelian model, which 
uses Bayesian calculations considering information from the full pedigree, including unaffected 
relatives. The performance of MMRpro may be similar to the Edinburgh and Premm1,2 models 
in the clinical setting, but further evaluation is needed. 
In conclusion, we have evaluated five easily applicable mutation prediction models for Lynch 
syndrome in a selected clinical population. The models have a high accuracy and cost-effective-
ness for detecting germline mutations in the mismatch repair genes. The Edinburgh and Premm1,2 
model had the best performance in an intermediate to high-risk setting and these models may 
well be of use in clinical practice. The poor calibration of the Leiden, UK-Ams and UK-Alt 
model hampers direct application of these mutation prediction models. Further evaluation of 
mutation prediction models across different settings is needed. 
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AbSTRACT
This study evaluated the use of genetic testing and time trends in hereditary non polyposis 
colorectal cancer (HNPCC), (attenuated) familial adenomatous polyposis ((A)FAP) and MU-
TYH associated polyposis (MAP) families. Eighty-seven families, who were diagnosed with 
disease causing mutations between 1995-2006, were included in this study. The families con-
sisted of 1547 individuals at risk. Data of these individuals were collected from medical records 
and family pedigrees. 
There was considerable interest in genetic testing with test rates of 41% in HNPCC families, 
42% in (A)FAP families and 53% in MAP families. The use of genetic testing was associated 
with age and parenthood. Despite the interest in genetic testing, many risk-carriers do not apply 
for testing. Moreover, time trend analysis showed a decline in test rate in HNPCC families. 
Studies evaluating the reasons for not testing are needed. Furthermore, a better implementation 
of genetic testing in clinical practice is desirable. 
Keywords:
(A)FAP, genetic testing, HNPCC, MAP, mutation carrier.
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INTRODuCTION
Hereditary Non Polyposis Colorectal Cancer (HNPCC) and Familial Adenomatous Polyposis 
(FAP) are the two most common hereditary colorectal cancer syndromes, accounting for 2-5% of 
colorectal cancer cases.1, 2 These syndromes are caused respectively by germline mutations in the 
MMR genes (MLH1, MSH2, MSH6 or PMS2) and in the APC gene.3-5 An attenuated form of FAP 
(AFAP) is characterized by the development of less polyps than in classical FAP (10-100 polyps 
vs. more that 100 polyps) at an older age. AFAP is associated with mutations in the APC gene 
or mutations in the MUTYH gene.6, 7 The latter is also known as MUTYH Associated Polyposis 
(MAP). HNPCC and (A)FAP are inherited in an autosomal dominant way, whereas MAP is 
recessively inherited. About 25% of the APC mutations are de novo.8, 9 
Genetic testing in HNPCC, (A)FAP or MAP family members has a considerable medical and 
psychological impact. Subjects with a known mutation can benefit from medical surveillance 
programs, while subjects without a mutation are relieved from anxiety and can be dismissed 
from surveillance. However, genetic testing can also be associated with negative effects such as 
an increased anxiety about one’s health, uncertainty about the future, social discrimination and 
financial consequences, for instance related to health care and life-insurances. 
Data on the use of genetic tests in clinical practice in HNPCC families are sparse. A few 
studies have reported genetic test rates ranging from 43 to 75%.10-12 Data concerning the genetic 
test rate in (A)FAP and MAP families are lacking. The aim of the present study was therefore to 
evaluate the use of genetic testing and time trends in molecularly confirmed HNPCC, (A)FAP 
and MAP families in a clinical setting. Furthermore, factors associated with the use of genetic 
testing were evaluated.
mATERIAL AND mETHODS
Subjects
In total, a cohort of 87 families diagnosed with a hereditary colorectal cancer syndrome at the 
department of Clinical Genetics of the Erasmus MC University Medical Center between 1995 
and 2006 was selected. Of these 87 families, 45 families were identified with a pathogenic 
germline mutation in the MLH1 (n=17), MSH2 (n=12), or MSH6 (n=16) gene. In 34 families a 
pathogenic mutation in the APC gene was identified and in eight families pathogenic mutations 
in the MUTYH gene. DNA analysis was performed at the Department of Human and Clinical 
Genetics of the Leiden University Medical Center or at the Department of Clinical Genetics of 
the Erasmus MC University Medical Center in Rotterdam. Subjects originating from families 
with a germline HNPCC gene mutation or with two germline MUTYH mutations were included 
if they were aged 18 years or older and in case of an a priori risk of 100%, 50% or 25% for carry-
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ing the mutation(s) (Table 1). Subjects originating from families with a germline APC mutation 
were included if they were aged 10 years or older and in case of an a priori risk of 100%, 50% 
or 25% for carrying the mutation. Unaffected parents and unaffected siblings of apparently de 
novo APC mutation carriers were also included.
Counseling procedure
The first relatives seeking genetic advice for colorectal cancer in the family, the initial coun-
selees, were healthy risk carriers as well as relatives affected by an HNPCC, (A)FAP or MAP 
related tumor or polyposis. In general, the identification of a causative germline mutation in 
a family was performed on blood DNA of affected individuals. If the initial counselee was a 
healthy risk carrier, affected relatives were approached to cooperate. After identification of a 
pathogenic mutation, the initial counselee was asked to inform all adult first- and second degree 
relatives of patients with an HNPCC, (A)FAP, or MAP related tumor or polyposis about the 
possibility of genetic testing. Written information about the inheritance of familial cancer, risks 
for developing cancer, the availability of diagnostic genetic testing and possibility of medical 
surveillance programs was available for relatives. Relatives who underwent genetic testing 
received one or more pre-test counseling sessions as recommended by the American Society 
of Clinical Oncology.13 Psychological support was available for relatives throughout the testing 
procedure.
Table 1. Definition of a priori risk groups.
A priori risk HNPCC (A)FAP MAP
100%* Person with a HNPCC related tumor or 
obligate carriers
Person with (attenuated) polyposis  
+/- CRC
Person with attenuated 
polyposis +/ - CRC
50% 1st degree relative to an affected person 
with an HNPCC related tumor or 
proven mutation
1st degree relative to an affected person  
with (attenuated) polyposis +/- CRC or 
proven mutation
25% Person with an unaffected living or 
deceased parent with a 50% risk
Person with an unaffected living or 
deceased parent with a 50% risk
Person with a sibling with 
attenuated polyposis +/ - CRC 
or 
two proven mutations
Parents Parent of an apparently de novo 
mutation carrier 
Siblings Sibling of an apparently de novo 
mutation carrier
* 100% a priori risk subjects may include phenocopies
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Data collection
All data were collected from family pedigrees and medical records. Data collection included 
sex, presence of an HNPCC related tumor or A(FAP) and MAP related polyposis or tumors, age 
at tumor diagnosis, age at time of genetic testing, parenthood and a priori risk (Table 1). 
The interval between the molecular diagnosis in the family and the individual genetic test was 
evaluated for HNPCC, (A)FAP and MAP families.
Time trend analysis regarding genetic testing was evaluated using data of genetic test use in 18 
HNPCC families 12 and 13 (A)FAP families who were molecularly diagnosed in the period 1995-
2000. These data were compared with the data of 27 HNPCC families and 21 (A)FAP families 
who were molecularly diagnosed in the period 2001-2006. All MAP families were molecularly 
diagnosed after 2001 and therefore not included in the time trend analysis.
Statistics
Data were submitted for statistical testing using the Statistical Package for the Social Sciences 
(SPSS Inc, Chicago, IL), version 12.0.1. Data are given as median and range or as mean with 
standard deviation when appropriate. Descriptive statistics were used to establish test rates of 
genetic testing. Chi square analysis was performed to calculate differences between the different 
a priori risk groups. A two-sided p value < 0.05 was considered significant. Univariate analysis 
was used to establish the influence of parenthood, gender and age on the use of genetic testing 
in 50% a priori risk subjects. Multivariate logistic regression analysis was used to establish 
the simultaneous influence of age, gender and parenthood on the use of genetic testing in 50% 
a priori risk subjects. Age was categorized into subjects younger or older than 50 years for 
HNPCC families. For the (A)FAP families, subjects were categorized into three groups, subjects 
younger than 18 years, aged 18-40 and older than 40 years. Subjects younger than 18 years were 
not included in the univariate and multivariate analysis regarding the influence of parenthood.
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RESuLTS
HNPCC families
The 45 HNPCC families consisted of 1230 living subjects, including 112 subjects with a 100% a 
priori risk, 640 subjects with a 50% a priori risk and 478 subjects with a 25% a priori risk (Table 
2). At the time of clinical ascertainment, 39 of the 45 families fulfilled the Amsterdam II criteria. 
The median follow-up time after identification of the family specific mutation was 82 months 
(10-140 months).
Genetic testing was used in 499 subjects (41%). Of the subjects with a 100%, 50% and 25% a 
priori risk for carrying the mutation, genetic testing was used in 85%, 52% and 15% respectively 
(p < 0.001 for 100% vs. 50% and p< 0.001 for 50% vs. 25%). Multivariate analysis showed 
that gender and parenthood were significantly associated with the use of genetic testing in 50% 
a priori risk subjects (Table 3). The effect of age was masked by having children, but was 
significantly associated with genetic testing in the multivariate analysis.
Table 2. Genetic testing and outcome in the 87 families
A priori risk 100% 50% 25% Residual risk
Parent alive Parent dead Total Parent* Sibling* Total
HNPCC 
families (n=45)
Number 112 640 279 199 478 1230
Tested 95 (85%) 330 (52%) 12 (4%) 62 (31%) 74 (15%) 499 (41%)
Mutation 
Carrier
91 (96%) 147 (45%) 1 (8%) 4 (6%) 5 (7%) 243 (49%)
(A)FAP families 
(n=34)
Number 46 102 31 26 57 34 48 287
Tested 43 (93%) 46 (45%) 0 3 (12%) 3 (5%) 15 (44%) 13 (27%) 120 (42%)
Mutation 
Carrier
41 (95%) 9 (20%) 0 0 0 0 0 50 (42%)
MAP families 
(n=8)
Number 8 22 30
Tested 8 (100%) 8 (36%) 16 (53%)
Mutation 
Carrier
8 (100%) 5 (63%) 13 (81%)
   homozygous 6 0
   heterozygous 0 5
    compound 
heterozygous
2 0
* of a subject with an apparently de novo APC mutation
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Twenty-eight percent of 50% a priori risk subjects decided to opt for genetic testing within one 
year after the molecular diagnosis in the family, 46% after two years and 52% after three years 
(Figure 1). 
Comparison of the genetic test rate for 50% a priori risk subjects who were found to be eligible 
for genetic testing during the period 1995-2000 and during the period 2001-2006 showed a 
significant decline in genetic test rate from 57% to 46% (p = 0.03).
(A)FAP families
The (A)FAP families consisted of 287 living subjects, including 46 subjects with a 100% a priori 
risk, 102 subjects with a 50% a priori risk, 57 subjects with a 25% a priori risk, 34 unaffected 
parents of an apparently de novo mutation carrier and 48 unaffected siblings of an apparently de 
novo mutation carrier (Table 2). The median follow up time after identification of the family-
specific mutation was 74 months (range 17-137 months).
Genetic testing was used in 120 subjects (42%). Of the subjects with an a priori risk of 
100%, 50% and 25% for carrying the mutation, genetic testing was used in 93%, 45% and 5% 
Table 3. Univariate and multivariate analysis of the 50% a priori risk subjects in the HNPCC and the APC mutation families.
Total Tested (%) Univariate OR (95% CI) p value Adjusted OR (95% CI) p value
HNPCC families (n=640)
Age
< 50 year 455 244 (54%) 1.3 (0.9-1.9) 0.1 2.5 (1.7-3.8) < 0.001
> 50 year 185 86 (46%)
Gender
Female 333 196 (59%) 1.8 (1.3-2.5) < 0.001 1.7 (1.2-2.4) < 0.01
Male 307 134 (44%)
Children
yes 301 199 (66%) 3.0 (2.2-4.3) < 0.001 4.1 (2.8-6.0) < 0.001
no 339 131 (39%)
(A)FAP families (n=102)
Age (categorized)
< 18 yr 22 10 (45%) 0.04 0.005
18- 40 yr 36 27 (75%) 0.5 (0.2-1.5) 0.6 (0.2-1.8)
> 40 yr 44 9 (20%) 2.5 (0.8-7.7) 8.1 (1.4-47.0)
Gender
 Female 50 25 (50%) 1.5 (0.7-3.2) 0.3 1.3 (0.6-3.1) 0.5
 Male 52 21 (40%)
Children* 
yes 30 14 (47%) 1.1 (0.4-2.8) 0.8 5.3 (1.1-24.4) 0.04
no 50 22 (44%)
* only for the 50% a priori risk subjects aged 18 years or older
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respectively (p < 0.0001 for 100% vs. 50% and p < 0.0001 for 50% vs. 25%) (Table 2). Of the 
parents and siblings of an apparently de novo mutation carrier respectively 44% and 27% used 
genetic testing. The test rate in 50% a priori risk subjects was significantly lower for subjects 
older than 40 years of age (Table 3). Multivariate analysis showed that age and parenthood were 
significantly associated with the use of genetic testing in 50% a priori risk subjects (Table 3).
Thirty-one percent of 50% a priori risk subjects decided to opt for genetic testing within one 
year after the molecular diagnosis in the family, 36% after two years and 39% after three years 
(Figure 1).
Comparison of the genetic test rate for 50% a priori risk subjects who were found to be 
eligible for genetic testing in the period 1995-2000 and in the period 2001-2006 showed no 
significant decline in genetic test rate from 47% to 43% (p = 0.2).
mAP families
The eight MAP families consisted of 30 living subjects, including eight subjects with a 100% a 
priori risk and 22 subjects with a 25% a priori risk (Table 2). The median follow up time after 
identification of the family specific mutations was 31 months (range 12-38 months). Genetic 
testing was used in eight 25% a priori risk subjects (36%) (Table 2). 
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Figure 1. Proportion of 50% HNPCC and (A)FAP risk subjects and 25% MAP risk subjects tested since identification of the familial mutation.
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DISCuSSION
There is a clear interest in genetic testing for hereditary colorectal cancer syndromes. However, 
more than half of the subjects at risk do not opt for testing. A higher genetic test rate would be 
desirable, since subjects without a mutation can be dismissed from burdensome surveillance.14-16 
Furthermore, preventive options are available for identified mutation carriers. Besides, subjects 
with a known mutation who have knowledge of their mutation status comply better with colo-
noscopy surveillance.17
A reason for refraining from testing may be a lack of adequate information about the possibility 
of testing. This may be due to the current procedure in the Netherlands. In The Netherlands, the 
initial counselee should inform all relatives. Studies on the efficiency of the current procedure 
and other possible procedures to inform risk carriers are needed. 
It is also possible that well-informed risk carriers refrain from genetic testing because of pos-
sible psychosocial consequences or the fear of screening. However, changes in distress amongst 
mutation carriers of cancer predisposition syndromes appear to be only temporary. Immediately 
after test disclosure there is increase in general anxiety. Carriers are able to cope with having the 
predisposition on the short as well as the long term.17-21 With respect to the burden of screening, 
the majority of HNPCC carriers experiences colonoscopic surveillance as uncomfortable. Nev-
ertheless, 88% of proven mutation carriers comply with colonoscopic surveillance.17  Another 
reason for declining genetic testing are the possible financial consequences such as higher costs 
for health insurances or a mortgage.22 
The genetic test rate is correlated with the a priori risk for carrying a mutation. It should however 
be taken into account that affected relatives (100% a priori risk) were actively recruited for 
genetic testing to identify the familial mutation. This probably contributed to the high test rate 
among 100% a priori risk subjects. The lower test rate in 25% a priori risk subjects may be due 
to a lower perceived cancer risk in this group. Risk carriers may feel “more safe” with a parent 
between them and the family with the predisposition. Not willing to violate the parent’s “right 
not to know” may be another factor that contributes to the difference in test rate in 25% a priori 
risk subjects with and without a deceased parent. 
In the HNPCC and (A)FAP families the uptake of the 50% a priori risk subjects was comparable 
(52% vs. 45%) and associated with age. The influence of age may be due to a decreased risk 
to carry the familial mutation with increasing age. Furthermore, there may be a decrease of 
perceived risk of cancer being healthy at an older age. 
Another factor associated with performing genetic testing among 50% a priori risk subjects 
is parenthood. In other cancer syndromes such as hereditary breast and ovary cancer the as-
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sociation between parenthood and genetic testing has also been observed.23 Genetic testing 
provides knowledge about the presence or absence of the cancer risks for offspring and parental 
responsibility is therefore a stimulation for testing. 
In our study female 50% a priori risk subjects from HNPCC families tended to undergo genetic 
testing more often. This finding is in contrast with previous studies which did not report a gender 
difference in the uptake of genetic testing in HNPCC families.10, 11, 24  However, female MMR 
mutation carriers have an higher risk for developing endometrial cancer and this could possibly 
influence the uptake of genetic testing among females.25, 26 Besides, in general women are more 
likely to use health care services compared to men.27, 28 
Time trend analysis showed a significant decline in the performance of genetic testing by 50% 
a priori risk subjects originating from HNPCC families. There were no major changes in the 
counseling procedure and staff at our department during the study period that can explain the 
observed decline. The fear of financial consequences is a known factor to refrain from genetic 
testing.22 The decline in genetic testing may therefore reflect a less favorable social situation for 
testing in The Netherlands in the past years. Professionals in the field should be aware of this and 
actively contribute to a good social situation for genetic testing. Further studies into the reasons 
for refraining from testing should be performed. 
Also, the awareness among health care providers should be improved. A previous study 
reported that 95% of American gastroenterologists were aware of genetic counseling, but only 
52% of the gastroenterologists were aware of genetic testing for FAP and 34% for HNPCC.29 
Therefore further implementation of genetic testing in clinical practice is needed.
In conclusion, the present study shows a clear interest in genetic testing for hereditary colorectal 
cancer syndromes. However, more than half of the subjects at risk do not opt for testing and in 
HNPCC families this proportion has increased over the past years. The reasons for refraining 
from testing should be further studied. Also, in view of the considerable medical benefit of 
genetic testing, social discrimination of possible mutation carriers should be minimized and 
the awareness of testing should be increased among at-risk individuals as well as health care 
providers. Further implementation of genetic testing in clinical practice is needed.
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AbSTRACT
Objective: To compare the sensitivity of autofluorescence endoscopy (AFE) and white light 
video endoscopy (WLE) for the detection of colorectal adenomas in high-risk patients belonging 
to Lynch syndrome (LS) or familial colorectal cancer (CRC) families.
Design: Prospective single centre study.
Setting: Tertiary referral centre.
Patients: Seventy-five asymptomatic patients originating from Lynch syndrome or familial 
CRC families.
Interventions: Patients were examined with either WLE followed by AFE or AFE followed by 
WLE. Back-to-back colonoscopy was performed by two blinded endoscopists. All lesions were 
removed during the second endoscopic procedure. Lesions missed during the second procedure 
were identified and removed on 3rd pass. The sensitivity calculations for colorectal adenomas 
were based on histology results.
main outcome measures: The difference in sensitivity between WLE and AFE for the detection 
of adenomas in patients with LS or familial CRC.
Results: At least one adenoma was detected in 41 (55%) patients. WLE identified adenomas 
in 28/41 patients and AFE in 37/41 patients; corresponding with a 32% increase. In total 95 
adenomas were detected, 65 by WLE and 87 by AFE, resulting in a significantly higher sensitiv-
ity of AFE compared to WLE (92% vs. 68%; p = 0.001). The additionally detected adenomas 
with AFE were significantly smaller than the adenomas detected by WLE (mean 3.0 mm vs. 4.9 
mm, p < 0.01). 
Conclusions: Autofluorescence endoscopy improves the detection of colorectal adenomas in 
patients with LS or familial CRC. The results of this study suggest that AFE may be preferable 
for surveillance of these high-risk patients.
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INTRODuCTION
The detection and removal of colorectal adenomas has been proven effective in reducing mor-
tality and incidence of colorectal cancer (CRC).1 Therefore, endoscopic surveillance is highly 
recommended in high-risk populations such as Lynch syndrome (LS) or familial CRC.2 Standard 
screening and surveillance colonoscopy is performed using flexible white light video endoscopy 
(WLE). However, with this technique 2-26% of adenomatous polyps are missed.3 Furthermore, 
flat and depressed adenomas are often invisible to WLE.4, 5 Such lesions reportedly make up 
36% of neoplasia in a standard population 6, and they are presumably more common in high-risk 
subjects. Identification of these lesions is especially important in these high-risk populations. In 
LS mutation carriers, the mortality due to colorectal cancer remains more than 10-fold increased, 
even when undergoing a (bi-)annual WLE colonoscopy screening.2 This may to a considerable 
extent be due to rapid progression of smaller, missed lesions. 
Autofluorescence endoscopy (AFE) is a technique specifically designed to probe large areas 
of mucosa to detect neoplasia. The technique has been approved by the U.S. Food and Drug 
Administration for use in bronchoscopy and may also be of special use in the colon.7 The tech-
nique is based on the phenomenon that when tissue is exposed to light of a short wavelength 
(typically blue light) some endogenous biological substances (fluorophores) are excited, leading 
to subsequent emission of fluorescence light of a longer wavelength. This phenomenon is called 
tissue autofluorescence.8 The technique does not require administration of fluorescent dyes. Sev-
eral pathological processes, in particular inflammation and neoplasia change the concentration 
and distribution of the various endogenous fluorophores in the tissue and consequently alter the 
tissue’s endogenous fluorescence. Other phenomena like the increase in mucosal thickness and 
variation in distribution of haemoglobin in early colonic neoplastic lesions leads to attenuation 
of the emitted tissue autofluorescence. In AFE the autofluorescent image is induced by using 
a white light source with a green filter. The tissue is thereby exposed to the remaining visible 
blue and red light. The reflected blue light is blocked by a filter in the CCD camera. The emitted 
green autofluorescence from the tissue and the reflected red light are used to obtain a false colour 
image. The system consisting of a light source, processor and dual CCD camera produces an 
image in which the normal colonic mucosa is depicted in cyan blue and adenomatous lesions in 
brick red. 
Available data indeed suggest that AFE can detect small or early stage lesions and flat or 
depressed adenomas with a high sensitivity compared to WLE.9, 10 However, prospective com-
parative studies with current standard video colonoscopy and autofluorescence endoscopy for 
surveillance of colorectal adenomas and CRC are missing. The aim of this study therefore was 
to compare the sensitivity of autofluorescence endoscopy and white light video endoscopy for 
the detection of colorectal adenomas in patients with LS or familial CRC.
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mETHODS
Study population
Patients aged 18 years or older scheduled for surveillance colonoscopy were eligible for this 
study if they originated from LS or familial CRC families. Patients were categorized as LS 
patients if they fulfilled the Amsterdam II criteria or if they carried a proven mutation in one 
of the mismatch repair genes (MLH1, MSH2 or MSH6).11 Patients were categorized as familial 
CRC if they had one first degree relative with colorectal cancer diagnosed at a young age (< 50 
years) or two first degree relatives regardless of age.12 
Patients with inflammatory bowel disease, familial adenomatous polyposis, Peutz-Jeghers 
syndrome, or juvenile polyposis were excluded from the study, as well as patients with a coagu-
lopathy or on anticoagulant therapy that could not be discontinued. 
The study protocol was approved by the institutional review board of the Erasmus MC Uni-
versity Medical Center, and informed consent for participation in the study was obtained from 
all subjects before inclusion.
Imaging systems
High definition white light video endoscopy was performed using a standard flexible video 
endoscope (CF160, Olympus Optical Co, Tokyo, Japan) connected to a xenon light source. 
Autofluorescence endoscopy was performed using the Onco-Life system (Xillix Technologies 
Corporation, Richmond, BC, Canada). The Onco-Life system consists of a metal-halide light 
source, processor and dual CCD camera that is attached to the eyepiece of a standard fiberoptic 
endoscope (CF40, Olympus Optical Co, Tokyo, Japan). The Onco-Life system operates in two 
modes providing both autofluorescence and conventional white light imaging. Modes can be 
switched instantly by pressing a lever on the camera head. 
In fluorescence mode, blue light (400-450 nm) triggers autofluorescence from the tissue 
within the endoscopic field of view. The emitted green fluorescence passes through a dichroic 
mirror and a 490-560 nm bandpass filter to an intensified CCD, whereas the red reflected light 
is projected on a second CCD. The processor combines the two images into a single dual colour 
digital image that can be displayed on a standard RGB monitor. The resolution and contrast of 
these images, although less than those of white light images, are sufficient to allow visualization 
of the usual features evident by standard endoscopy.
In the white light mode, the Onco-Life system light source provides a standard broad-spectrum 
light (400-700 nm) for illumination of the endoscopic field. The reflected light is captured by 
a colour CCD camera. The white light images are processed and displayed in the conventional 
manner.
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Endoscopic procedure
All patients were prepared for colonoscopy by ingesting 4 litres of a standard oral polyeth-
yleenglycol-electrolyte lavage solution (Coloforte, Ipsen Farmeutica BV, the Netherlands). All 
patients received 40 mg butylscopolamine intravenously to improve visualization of the colon. 
Colonoscopy was performed under conscious sedation with midalozam in combination with 
fentanyl citrate, and cardiopulmonary monitoring was used. 
All patients underwent two colonoscopic examinations in one session (Figure 1). An indepen-
dent observer (DR or PP) recorded every macroscopically visible lesion suspicious of adenoma 
during withdrawal. Every procedure was videotaped and every lesions was immediately stored 
as a JPEG still image. Each lesion was graded by the endoscopist with respect to size (in mil-
limetres, by comparison to the known diameter of an open biopsy forceps), morphology (flat 
or depressed, sessile, polypoid), and location. The latter was done both by measurement of 
the distance in centimetres from the anal verge with a fully stretched endoscope, and by iden-
tification of the located segment of the colon (i.e. caecum/ ascending colon/ transverse colon/ 
descending colon/ sigmoid/ rectum). The first colonoscopy was performed with either a standard 
high definition video colonoscope (WLE) or with autofluorescence endoscopy (AFE) by an 
experienced endoscopist (Figure 1). All lesions were left in situ. Immediately after the first 
endoscopic procedure, the first endoscopist left the endoscopy suite and a second experienced 
endoscopist, who was unaware of the results of the first endoscopic procedure, performed the 
second endoscopic procedure with the alternative endoscopic method. All endoscopists involved 
had similar adenoma detection rates over the past years as identified from our endoscopy data-
base, and endoscopists alternated with respect to the type of endoscopy performed in this study 
(WLE or AFE). All identified lesions were removed during the second endoscopic procedure and 
sent in for histology. After finishing the second procedure, the independent observer unblinded 
the results of both WLE and AFE. 
Lesions found during WLE and AFE were matched based on the location in the colon and the 
comparison of the photographs taken during both procedures of any lesions. AFE was switched 
back to WLE only for the subsequent polypectomy. In case of a switch back for stools, there was 
immediately a switch back to AFE to examine the remaining colonic mucosa to ensure that the 
colonic mucosa was not assessed by WLE.
In case lesions had been detected during the first endoscopic procedure but missed by the 
second procedure, the colon was re-examined on a third pass with either WLE or AFE to remove 
lesions left in situ (Figure 1). 
Data collection
Demographic data, medical history, family history, known mismatch repair gene mutations, drug 
use, degree of cleansing of the colon (1 excellent, 2 good, 3 moderate, 4 poor), endoscopic 
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withdrawal time of each colonoscopy and all adverse events were recorded in the case record 
form (CRF). The withdrawal time was determined from a central review of videos by the first 
author (DR) and included the time for withdrawing the endoscope from caecum to removal from 
the rectum, without the additional time needed to evaluate suspicious lesions and/or to perform 
polypectomy. 
Figure 1. Flow chart study design
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All removed lesions were stained with haematoxylin and eosin and assessed by an experienced 
GI pathologist, who was blinded for the macroscopic aspect of the lesion. Lesions were catego-
rized by the pathologist as hyperplasia, adenoma (tubular, tubulovillous, villous or serrated) or 
carcinoma. Neoplasia was defined as the presence of adenoma or carcinoma in the specimen.
Adverse events were defined as any event during the study which impaired the well being of the 
patient, including changes in the physical, psychological or biochemical condition of the patient, 
whether or not considered procedure related. The adverse events were categorized into events 
caused by 1) the autofluorescence endoscopy, 2) the white light endoscopy, or 3) the polypec-
tomy. Serious adverse events included 1) events that were fatal or life threatening, 2) events that 
were permanently disabling, 3) events that required hospitalization and 4) complications due to 
the endoscopic procedure including bleeding and perforation. Date of onset, duration, intensity, 
action taken and outcome of the event were recorded on the CRF.
Outcome parameters
The primary outcome parameter was the difference in sensitivity between WLE and AFE for the 
detection of adenomas during colonoscopy in patients with LS or familial CRC. 
The secondary outcome parameters were: 1) the histological difference of the lesions detected 
only by WLE or only by AFE; 2) withdrawal time of the procedure for WLE and AFE, and 3) 
the size of the lesions detected with WLE and AFE.
Sample size calculation
Based on data on file of patients with LS or familial CRC who had undergone surveillance by 
WLE in 2004 in our department, at least one lesion was expected in 60% of patients. Auto-
fluorescence was considered to be of benefit when 20% more adenomas would be detected in 
comparison with WLE 13. Based on an a of 0.05 and a power of 0.80 the required sample size 
was 100 patients (Mc Nemar’s test of equality of paired proportions, nQuery Advisor). 
The study protocol required an interim analysis after 50 enrolments. If a highly significant dif-
ference in the primary measure outcome was found (p <  0.01; to limit the risk of a false positive 
finding), the study would be terminated. Based on the interim analysis, the study was terminated 
after 51 patients. However, in the original study protocol AFE was routinely performed after 
WLE. In order to control for unintended biases we extended the study by performing back-to-
back colonoscopy in the reverse order, i.e. AFE followed by WLE. Based on the results of the 
interim analysis (adenoma detected in 39% of patients with WLE compared to 59% with AFE 
and thus a 50% increase in adenoma-positive patients during AFE in comparison with WLE) and 
using an a of 0.05 and a power of 0.80, the required sample size for the study extension study 
was 22 patients (Mc Nemar’s test of equality of paired proportions, nQuery Advisor). 
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Statistical analysis
Data were analyzed with the Statistical Package for the Social Sciences (SPSS), version 12.0. 
Data are given as mean and standard deviation.  Results of WLE and AFE were compared with 
each other and with histology results. These analyses ignored correlations between findings 
within patients.
The sensitivity of WLE and AFE for adenomas was calculated using histology as the standard. 
The McNemar’s test was used to calculate differences between WLE and AFE regarding the 
number of adenoma positive patients, the sensitivity for adenomas and the detection rate of 
non-adenomatous lesions. The Mann-Whitney U test was used to calculate differences in the 
size of lesions detected by WLE and AFE only. The Fisher exact test was used to calculate 
differences in the endoscopic prediction and morphology of detected adenomas. The paired 
t-test was used to compare the endoscopic withdrawal time of AFE and WLE. Multivariable 
proportional odds logistic regression analysis was performed to identify possible correlations 
between the withdrawal time and the number of adenomas detected with each technique, and for 
the difference in number of adenomas detected against the difference in the withdrawal times. A 
two-sided p value of less than 0.05 was considered statistically significant.
RESuLTS
In total 76 patients gave informed consent for inclusion in the study. One of them could not be 
included because back-to-back colonoscopy could not be performed due to very poor bowel 
preparation. The remaining 75 were included in the trial. Fifty-one patients were evaluated by 
WLE followed by AFE and 24 patients were evaluated by AFE followed by WLE (Figure 1). 
Forty-one (55%) patients fulfilled the criteria of familial CRC, thirty-four (45%) patients were 
classified as LS patients. Twenty-nine of the latter 34 (85%) patients were proven mutation 
carriers, whereas the other five fulfilled the Amsterdam II criteria, but no gene mutation had so 
far been identified in them. Thirty-four (45%) of the 75 patients were male and the mean age of 
the study population was 48 (± 12) years. Bowel preparation was excellent in 31 (41%) patients, 
good in 27 (36%) patients and moderate in 17 (23%) patients. The caecum was intubated in all 
WLE and AFE procedures. No complications occurred during or after WLE and AFE procedures.
A third inspection was required in twenty-six (35%) patients for the removal of 44 lesions. In 
22 of them, this third inspection was necessary for removal of 36 lesions that had been identified 
during WLE, but were missed during subsequent AFE (Table 1). Histology showed that 3 (8%) 
of these 36 lesions were adenomas, the remaining 33 (92%) were hyperplastic lesions. In the 
remaining 4 patients requiring a third inspection, this was done to remove eight lesions that had 
been identified during AFE, but were missed during subsequent WLE. Histology showed that all 
eight (100%) lesions were adenomas.
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In this study, a total of 173 lesions were detected; 3 colorectal cancers, 95 adenomas and 75 
hyperplastic lesions. AFE detected a total of 123 lesions, while WLE detected 129 lesions. 
(Table 1). 
The mean withdrawal time of AFE was significantly longer than that of WLE (11.3 ± 3.9 vs. 
9.8 ± 3.0 minutes, p < 0.001, paired t-test). Multivariable proportional odds logistic regres-
sion analysis however revealed no significant relation between withdrawal time and number of 
adenomatous lesions detected with both techniques (p = 0.29). 
Adenoma-positive patients
Of the 75 patients included, 41 (55%) were found to have one or more adenomas. WLE detected 
one or more adenomas in 28 patients, while AFE detected one or more adenomas in 37 patients. 
This 32% increase (95% CI –0.01 – 0.23) in the number of adenoma-positive patients identified 
by AFE was significant (p = 0.03). Twenty-four (59 %) of the forty-one patients were found to 
be adenoma-positive by both WLE and AFE. Furthermore, WLE detected adenomas in four pa-
tients in whom no neoplastic lesions were detected by AFE. In contrast, AFE detected adenomas 
in 13 other patients in whom WLE detected no abnormalities. Of these 13 patients, seven were 
classified as familial CRC and six as LS. 
Table 1. Detected lesions by WLE and AFE
Endoscopic modality WLE + AFE WLE only AFE only
Type of lesion
Adenoma (n = 95)
Size
≤ 5 mm 47 8 29
6-9 mm 7 0 1
≥ 10 mm 3 0 0
Morphology
flat 4 1 6
sessile 45 5 21
pedunculated 8 2 3
Histology
Tubular adenoma 54 8 29
Tubulovillous adenoma 2 0 0
Serrated adenoma 1 0 1
Colorectal carcinoma (n=3) 3 0 0
Non adenomatous lesions (n=75)
Hyperplastic polyps  19 42 14
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Neoplasia detection rate
In total 98 neoplastic lesions were detected in our study population; 91 tubular adenomas with 
low-grade dysplasia, 2 tubulovillous adenomas with low-grade dysplasia, 2 serrated adenomas, 
and 3 adenocarcinomas. Fifty-seven of the 95 (60%) adenomas were detected by both WLE 
and AFE, including two tubulovillous adenomas with low-grade dysplasia and one serrated 
adenoma. Thirty-eight of the 95 (40%) adenomas were only seen with one of the two light 
techniques. WLE enabled detection of 8 adenomas that were missed by AFE, resulting in an 
overall adenoma detection rate by WLE of 68% (65/95) (Table 2). Of the latter eight adenomas, 
all had a size ranging from 3-5 mm. Seven of the eight adenomas had a sessile morphology, 
while one had a pedunculated morphology. All the eight adenomas were located in the proximal 
colon, two in the caecum, four in the ascending colon and two in the transverse colon. AFE, 
on the other hand, detected 30 additional adenomas that were not seen with WLE, resulting in 
an adenoma detection rate of 92% (87/95). AFE thus enabled the detection of 34% (95% CI 
-0.34 - -0.11) more adenomas than WLE. 
Each lesion was immediately graded by the endoscopist as either non-adenomatous or suspicious 
for adenoma. Forty-nine (75%) of the 65 detected adenomas by WLE were correctly classified 
by the endoscopist, while 80 (92%) of the 87 adenomas detected by AFE were correctly classi-
fied (p= 0.003, Fisher exact test).
The sensitivity of AFE for the detection of adenomas was significantly higher (92% vs. 68%, p = 
0.001, McNemar’s test) than that of WLE. This difference in detection rate between both meth-
ods was observed for both the endoscopists. The majority (16/30) of the adenomas detected by 
AFE only were located proximal to the splenic flexure. The mean size of the adenomas detected 
by AFE only was significantly smaller than the size of those detected by both WLE and AFE 
(3.0 ± 1.1 mm versus 4.9 + 2.1 mm; p< 0.001, Mann Whitney U test). Eleven (10%) adenomas 
were flat, 10 of them were detected by AFE compared to 5 by WLE (p = 0.063, Fisher exact test). 
Table 2a. Detection of adenomas with WLE and AFE
WLE
Detected Undetected
AFE
Detected 57 30
Undetected 8 0
Table 2 b. Detection of hyperplastic polyps with WLE and AFE
WLE
Detected Undetected
AFE
Detected 19 14
Undetected 42 0
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Non-adenomatous lesions
A total of 75 hyperplastic lesions were identified. WLE detected more hyperplastic lesions than 
AFE (81% vs. 44%, p = 0.001, McNemar’s test).   
Lynch syndrome versus Familial Colorectal Cancer
Of the 41 patients with one or more adenoma, 14 (34%) were classified as LS patients while the 
remaining 27 (66%) were classified as familial CRC patients (Table 3). 
DISCuSSION
This study has compared the yield of autofluorescence endoscopy with high definition white 
light video endoscopy for the detection of adenomatous lesions in a high-risk population. Both 
techniques yielded an equal number of lesions. However, AFE identified more adenomas includ-
ing flat and serrated adenomas, whereas WLE identified more hyperplastic lesions. Using AFE, 
the overall adenoma detection rate increased significantly by 34%, corresponding with a higher 
sensitivity of AFE compared to WLE (92% vs. 68%, p = 0.001). Also, AFE identified a signifi-
cant 32% more patients with adenomas. This yield of AFE compared to WLE is slightly higher 
than in a previous Canadian study, which reported an increased adenoma detection rate of 18% 
with AFE.13 The Canadian study population consisted of patients with an indication for surveil-
lance after previous adenoma or colon cancer resection, while our study population consisted 
of high-risk LS and familial cancer patients. Furthermore, the Canadian study had a somewhat 
different design, as the white light mode and autofluorescent modality were compared during the 
same procedure by the same endoscopist. This by definition meant that the endoscopist while do-
ing AFE was aware of the white light mode results. This contrasted with the currently presented 
study in which video WLE and AFE were performed by independent endoscopists unaware 
Table 3. Adenoma detection rate and size per patient group
Patient group Lynch Syndrome Familial Colorectal cancer
Adenoma positive patients (n) 14 27
Adenoma (n)
WLE + AFE 17 40
WLE only 4 4
AFE only 9 21
Mean size (± SD)
WLE + AFE 6.1 (± 2.3) mm 4.8 (± 1.7) mm
AFE only 3.0 (± 1.3) mm 3.1 (± 1.1) mm
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of the results of the other procedure. These differences may explain the level of difference in 
adenoma detection rate. More importantly, both studies consistently support the hypothesis that 
AFE significantly increases the detection of colorectal adenomas. 
The higher detection rate of AFE could also be influenced by the experience of the endoscopist. 
However, both endoscopists in our study were highly experienced with a similar level of en-
doscopic competence and with similar adenoma detection rates in the past during surveillance 
colonoscopies.
A strength of our study was that AFE and WLE were performed cross over. In the original 
study design AFE was routinely performed after WLE (n = 51). However, as this could have 
introduced bias, the study was extended with 24 additional patients. These patients underwent 
back-to-back colonoscopy in a reverse order, i.e. AFE followed by WLE.  The current study 
design enabled a true comparison of the diagnostic yield of both WLE and AFE. All endoscopies 
were done by two independent endoscopists who were unaware of the results of the prior endos-
copy instead of a design with one endoscopist and segmental unblinding. 
A potential shortcoming of our study is the difference in withdrawal time between WLE and 
AFE. Previous studies have reported that a longer withdrawal time is associated with improved 
adenoma detection.14-16 In our study the mean endoscopic withdrawal time for both WLE and 
AFE was significantly longer than the recommended minimum of six minutes.17, 18 There was no 
time restraint on either procedure, and the endoscopists were aware that the patients participat-
ing in the study were high-risk cases. Withdrawal with AFE averaged two minutes more than 
with WLE (11.3 vs. 9.8 minutes). This can in part be explained by the sensitivity of AFE to stool 
particles demanding additional cleansing. Stool particles can have the same red appearance as 
adenomatous tissue. For this reason, any ‘red flag’ that is spotted needs to be checked with white 
light also, requiring switching between both light modalities of the endoscope. In the case of a 
switch back for stool we immediately switched back to AFE, ensuring that the colonic mucosa 
was not assessed by WLE. In case of an adenoma, the switch back to WLE was extended for 
the duration of the polypectomy, after which AFE was continued for the remainder of the colon. 
One might consider the switching back as a major limitation of AFE, but this should be balanced 
against the additional number of detected adenomas with AFE. Most importantly, the difference 
in adenoma detection rates was not explained by the difference in withdrawal time between the 
two techniques (p = 0.29) (Figure 2).
In our study, the adenomas detected by AFE only were significantly smaller than those detected 
by WLE, and mostly had a tubular histology with low-grade dysplasia. Adenomas in LS patients 
seem to progress more rapidly (2 to 3 years) to invasive colorectal cancer compared to those 
in the general population (8 to 10 years), so also smaller lesions are considered of particular 
importance in our patient category.19 Removal of these low grade adenomas is mandatory, as 
rapid progression of small adenomas to invasive cancer is one of the likely explanations of the 
interval cancers that occur in LS despite surveillance colonoscopy.20, 21
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The number of hyperplastic lesions detected by AFE was significant lower than the number 
detected by WLE. Hyperplastic lesions do not exhibit neoplastic changes that might influence 
the tissue autofluorescence. During AFE, hyperplastic lesions do not appear as ‘flagged’ lesions 
but in fact only appear as irregularity of the mucosal surface, sometimes with minimal red or 
white coloration that can be distinguished from a background with a normal autofluorescence. 
One could consider the lower detection rate of hyperplastic lesions as an additional benefit of 
AFE, as hyperplastic lesions generally do not carry a malignant potential and their removal 
is associated with costs and a small but relevant complication risk. On the other hand, it has 
been acknowledged that colorectal carcinoma also can develop via the “serrated” pathway from 
hyperplastic polyps to sessile serrated polyps to carcinoma.22 In this respect, it is important to 
note that AFE enabled identification of all the serrated adenomas. 
Figure 2. Correlations between the endoscopic withdrawal time and detection rate of colorectal adenomas for WLE and AFE. The dots 
represent the number of detected adenomas (y axis) and the corresponding endoscopic withdrawal time (x axis) for WLE and AFE.
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Our study demonstrated that AFE is a suitable and reliable endoscopic technique for the detection 
of colorectal adenomas in Lynch syndrome as well as familial CRC patients. Other endoscopic 
techniques to improve the detection of adenomas include pancolonic chromoendoscopy and 
narrow band imaging. Pancolonic chromoendoscopy has been shown to improve the detection 
of small adenomas with low-grade dysplasia. This technique has been evaluated in a number 
of studies, including studies with Lynch syndrome patients.23, 24 However, pancolonic chromo 
endoscopy is time consuming because of the required dye spraying and therefore less practical 
in routine practice. Narrow band imaging (NBI) uses blue light which penetrates the mucosa less 
deeply than white light and the reflected light produces an image with greater mucosal detail. 
With NBI, the adenoma surface has a darker brown color than the adjacent normal mucosa and 
thus may highlight adenomas for detection. The value of NBI in high-risk patients is not yet 
clear. A recent study reported that the use of NBI did not increase the adenoma detection rate 
in comparison with WLE 25, while another study reported an significant increase in the number 
of adenoma positive patients.26 More studies evaluating NBI are needed to evaluate the yield of 
NBI in high-risk patients.
In conclusion, the use of autofluorescence endoscopy improves the detection of colorectal 
adenomas in patients with LS or familial CRC in comparison with video colonoscopy. Although 
more time consuming, the additional value of AFE is mainly in the detection of small lesions, 
which is for this specific population of clinical relevance. Therefore, AFE may be considered for 
colonoscopic surveillance of these high-risk patients.
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GENERAL DISCuSSION
Identification of Lynch syndrome remains a clinical challenge requiring a multi disciplinary 
approach. The absence of specific diagnostic features, such as the abundant number of polyps 
as seen in Familial Adenomatous Polyposis, and the geno- and phenotypic heterogeneity makes 
identification of Lynch syndrome patients difficult. Good characterization of the risks associ-
ated with the different causative germline mutations forms the basis for the identification of 
Lynch syndrome families.1 Clinical criteria such as the Amsterdam Criteria II 2 and the revised 
Bethesda guidelines 3 have been developed to identify families at risk for Lynch syndrome, as 
well as mutation prediction models. However, the optimal identification of MMR-gene muta-
tion carriers is still a subject of debate. Identification of Lynch syndrome risk carriers is of 
utmost importance because these subjects are at risk for developing colorectal cancer. Adequate 
colonoscopic surveillance increases the survival of these subjects. Therefore, evaluation of the 
uptake for genetic testing once a germline mutation is detected in a family is important, as well 
as optimizing surveillance tools. In this thesis all these aspects of Lynch syndrome are studied.
Cancer risk in Lynch syndrome
The most common cancer seen in Lynch syndrome is colorectal cancer (CRC), followed by 
endometrial cancer. However, other cancers such as stomach, small bowel, ovary, upper uro-
epithelial tract, biliary tract, skin and brain also occur at higher rates compared to the general 
population.4-13 Compared to the general population, proven mutation carriers have a significantly 
higher risk for developing CRC.14 The extend of this increased risk for CRC depends on the 
affected mismatch repair gene and gender. At age 70 years, the cumulative risk is 78% for male 
MLH1 mutation carriers, while the cumulative risks for male MSH2 and male MSH6 mutation 
carriers are 57% and 54% respectively (Chapter 3). The cumulative risks for CRC in females 
are lower compared to males, 57% for MLH1, 52% for MSH2 and 30% for MSH6 mutation 
carriers (Chapter 3).  The risk for endometrial carcinoma is 61% for female MSH6 mutation 
carriers (61%), while in female MLH1 and MSH2 mutation carriers the risk is 25% and 49%, 
respectively. 
Diagnostic tools for Lynch syndrome
The different phenotype of MSH6 mutations families is important for the identification of Lynch 
syndrome families. The majority of previously reported data includes Lynch syndrome patients 
with mutations in the MLH1 and MSH2 gene, accounting for approximately 90% of all Lynch 
syndrome cases.15-18 However, our detection rate of MSH6 mutations equals that of MLH1 and 
MSH2.19 The main reason that MSH6 mutation families are underreported is the different risk 
profile. MSH6 mutation families are less likely to fulfill current clinical criteria, the Amsterdam 
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Criteria II and the revised Bethesda guidelines, thereby decreasing the identification of Lynch 
syndrome. To optimize identification of MSH6 mutation families, families with a clustering of 
late onset endometrial carcinoma should also be included for MSI and/or IHC analysis. 
Another tool to identify Lynch syndrome families are mutation prediction models. In recent 
years several mutation prediction models have been developed. Some of these models use 
multivariate logistic regression to predict the likelihood based on personal and family history of 
Lynch syndrome associated tumors.20-24 Parametric models, on the other hand, use more input 
data, such as information of unaffected relatives of the counselee or the results of tumor MSI 
analysis. In contrast with regression models, parametric models are able to predict the likelihood 
of a MLH1, MSH2 or MSH6 mutation separately, while regression models predict the likelihood 
of carrying any mismatch repair gene mutation. 
Few studies so far have evaluated prediction models, of which the PREMM1,2 model have 
been validated more extensively with population based data from Spain.25, 26 Although the 
sensitivity of the PREMM1,2 model is high (98%), a major disadvantage is the fact that it does 
not take into account MSH6 mutations. Another prediction model, the Edinburgh model, has the 
advantage of predicting the probability of MLH1, MSH2 and MSH6 mutations. In our population 
of Lynch syndrome families, both the Premm1,2 and Edinburgh model had the same sensitivity 
for predicting mutations (98%), but their specificity was low, 22% and 9% respectively (chapter 
5). Adding MSI and IHC results yielded an increase in the specificity for detecting a mutation 
to 82% for the Premm1,2 model and 90% for the Edinburgh model. The Edinburgh model, is 
more suitable for use in clinical practice because of its capability to predict mutations in three 
different MMR genes. Prediction models seem to be promising but their clinical value still has 
to be determined. User-friendly interfaces are needed to make the input of data more easy and 
orderly. Accessibility through the World Wide Web will increase the use of these models. 
In our study, we evaluated families already referred to a clinical genetics department. In this 
setting both extending revised Bethesda guidelines and prediction models are useful tools to 
identify MLH1, MSH2 as well as MSH6 mutation families. However, the use of these tools in 
routine clinical practice of other specialists is suboptimal 27 and the referral of patients to a de-
partment of Clinical Genetics is not optimal, resulting in the underdiagnosis of Lynch syndrome. 
Also the contribution of PMS2 germline mutations to Lynch syndrome becomes increasingly 
clear.28 Because of the reduced penetrance of PMS2 mutations, compared to the other Lynch 
syndrome genes 29 both extended revised Bethesda guidelines and prediction models such as the 
PREMM1,2 and Edinburgh model are likely to miss PMS2 families. Efforts are done to imple-
ment MSI-testing and/or immunohistochemistry for the MMR-genes in routine clinical practice 
of the pathologists (MIPA). However further studies are needed to come to the most reliable and 
cost-effective way to identify LS families.  
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The use of genetic testing in LS families
After identification of a mutation in a family, all relatives can be offered direct mutation analysis 
of the affected mismatch repair gene. Healthy individuals, who carry the familial mutation are 
likely to benefit most from the offered colonoscopic surveillance. The current uptake of genetic 
testing by relatives at 50% risk of carrying the mutation is unexpectedly low, 52% of subjects 
with a 50% risk opted for genetic testing within three years after identification of a mutation 
in the family (chapter 6). There are several reasons for the low uptake like possible financial 
consequences such as higher costs for health insurances or limitation for a mortgage.30 However, 
another important reason for the low uptake is probably a lack of adequate information about 
the possibility of testing. This may be due to the current procedure in the Netherlands. In The 
Netherlands, the initial counselee should inform all relatives. Therefore, studies on the efficiency 
of the current procedure and other possible (more active) procedures are needed.
Colorectal cancer surveillance
The main goal for optimizing Lynch syndrome identification is to offer CRC surveillance.
The surveillance program for Lynch syndrome includes colorectal surveillance by biennial colo-
noscopy starting from the age of 20-25 years. Interval CRC are seen with a triennial surveillance 
colonoscopy, but the risk for developing an invasive CRC within a 2-year period is small.31, 32 
There is evidence that colonoscopy surveillance is effective in reducing the incidence and mor-
tality of colorectal cancer.33-36 Currently, colonoscopy surveillance is performed with white light 
endoscopy, however this technique has a miss rate of 2% for large adenomas (> 10 mm) and 26% 
for small adenomas (< 5mm).37 In Lynch syndrome, especially small and flat adenomas are prone 
to malignant transformation compared to the general population.38, 39  Detection of these small 
and flat adenomas is important and new endoscopic modalities are needed. Chromo endoscopy 
is an endoscopic modality in which dye is used to improve the visualization of the colonic 
mucosa. Although this technique detects more adenomas 40 it is more time consuming due to the 
dye spraying. Another technique is narrow band imaging. This technique highlights superficial 
capillaries in the mucosa. Neoplasia in the mucosa has an increased vascular density and thus 
can be easily detected by narrow band imaging (NBI). This technique also has a higher adenoma 
detection rate than conventional colonoscopy and may be suitable for surveillance of Lynch 
syndrome.41 However, a study evaluating NBI in 471 asymptomatic patients showed no signifi-
cant difference between conventional colonoscopy and NBI if the procedure was performed by 
a experienced gastroenterologist.42 Therefore, the additional value of NBI in the surveillance of 
Lynch syndrome is still disputable. Another promising technique is autofluorescence imaging. 
This technique uses the endogenous autofluorescence of tissue to detect abnormalities. Colorec-
tal neoplasia generates another autofluorescence image compared to normal mucosal tissue. This 
distinct pattern can be used to discriminate between adenomas and normal tissue. In a series 
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of 75 patients with Lynch syndrome or familial cancer, the use of autofluorescence endoscopy 
resulted in 34% increase of adenoma detection rate (chapter 7). The majority of the additional 
adenomas detected were smaller than 5 millimeters, emphasizing the potential diagnostic value 
of this technique. One could discuss the value of finding such small adenomas, since these 
adenomas may also be seen, in somewhat larger size, when surveillance is repeated after 2 
years. However, detecting these small adenomas is important in this high-risk group, because 
CRC may develop out of these small adenomas, even within two years. Further evaluation of the 
autofluorescence technique, narrow band imaging or chromo endoscopy is needed. Long follow 
up studies are needed to evaluate the effect on adenoma and CRC incidence and mortality rate. 
Nevertheless, in Lynch syndrome these techniques seem to be superior to white light endoscopy.
CONCLuSION
The studies in this thesis help to better characterize LS and evaluate the tools to identify LS 
families. Despite the available diagnostic tools the identification of Lynch sydrome remains 
difficult. Current clinical criteria and mutation prediction models are not sufficient enough to 
identify all Lynch syndrome families missing a large proportion of MSH6 and PMS2 families. 
Routinely molecular screening is a better tool for the identification of Lynch syndrome, but 
analyses of the feasibility, diagnostic yield and cost effectiveness of molecular screening in 
all newly diagnosed colorectal and endometrial cancer cases in the Dutch situation should be 
performed. The current procedure to inform individual at risk after the detection of a MMR 
germline mutation in a family should be evaluated and new strategies must be studied to optimize 
the use of genetic testing. With respect to surveillance of colorectal cancer in Lynch syndrome, 
new endoscopic modalities should be further evaluated and compared with conventional white 
light colonoscopy before implementation in routine clinical practice can take place. So, further 
research on diagnostic tools and endoscopic modalities is necessary to improve the detection and 
surveillance of Lynch syndrome. 
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Lynch syndrome (LS) is a hereditary cancer syndrome caused by mutations in the mismatch 
repair genes (MMR), MLH1, MSH2, MSH6 and PMS2. It is characterized by a high risk of 
colorectal and endometrial cancer, but also other tumors occur. Lynch syndrome is responsible 
for 2-5% of all CRC cases. However, the diagnosis of Lynch syndrome is hampered by the 
absence of specific diagnostic features, such as the presence of many adenomatous polyps in 
the colon. In addition, the currently used clinical criteria are sub optimal and new diagnostic 
strategies are needed to identify Lynch syndrome families.
The general aims and outline of this thesis are described in chapter 1 and in chapter 2 a 
general overview of different aspects of Lynch syndrome is given. 
In chapter 3 we calculated the lifetime risk of colorectal cancer and endometrial cancer using 
a population of 67 Lynch syndrome families who were counselled at the Department of Clinical 
Genetics of the Erasmus MC University Medical Center in the period 1994-2007. The study 
population consisted out of 246 proven mutation carriers. This study confirms the high risk of 
colorectal and endometrial cancer in Lynch syndrome. The highest risk for colorectal cancer 
was found for MLH1 mutation carriers (78% for males and 57% for females). In contrast, MSH6 
carriers had the highest risk for developing endometrial cancer (61%).  Furthermore, we found 
that each mutated gene has a distinguishable cancer risk profile.
In Chapter 4 the contribution of MSH6 gene mutations in families that were analysed for 
Lynch syndrome in a diagnostic setting was evaluated. A total of 108 families suspected of LS 
were tested for germline mutations of the MMR genes during the period 2000-2006. Previous 
reports showed that mutations in the MLH1 and MSH2 genes account for almost 90% of Lynch 
syndrome cases, while mutations in the MSH6 gene account for approximately 10% of cases. In 
our study cohort we found a mutation in 23 families (7 MLH1, 4 MSH2 and 12 MSH6). However, 
53% of the proven mutation families were detected with a MSH6 mutation. Furthermore, we 
found that the Amsterdam Criteria II failed to identify the majority of the MSH6 families while 
the revised Bethesda guidelines did identify the majority of MSH6 families. Nevertheless, we 
also detected MSH6 mutations in Bethesda negative families presenting with clustering of late 
onset endometrial carcinoma. The results of this study suggest that that the previously reported 
incidence of 10% MSH6 mutations is an underestimation. Awareness of the high prevalence of 
endometrial carcinoma combined with the later onset of both CRC and endometrial carcinoma 
in MSH6 mutation families could result in an improved detection of MSH6 mutation families.
Chapter 5 describes a study in which we evaluated the usefulness of five different predic-
tion models for the detection of Lynch syndrome. Data of 321 families, including 66 mutation 
families, were used as input for the prediction models. We found that all prediction models 
discriminated well between high risk and low risk probands. Among the five models considered, 
the Premm1,2 and Edinburgh model had the best performance in predicting mutation carrier-
ship, because these two models had the highest discriminative ability and were well calibrated. 
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Combining prediction models with tumour MMR deficiency analysis resulted in a substantial 
increase of the specificity. Furthermore, the use of prediction models could lead to lower costs 
compared to a strategy of performing tumour MMR deficiency analysis in all CRC cases. How-
ever, before prediction models can be implemented in clinical practice further evaluation of 
these models across different settings is needed. 
The detection of a familial MMR gene mutation enables individuals at risk to obtain certainty 
about whether they inherited the Lynch susceptibility or not. Lynch syndrome is inherited in an 
autosomal dominant fashion. Therefore children of MMR gene mutation carriers have 50% risk 
to carry the familial mutation. If tested negative, relatives can be dismissed from surveillance 
while mutation carriers can benefit from surveillance. In chapter 6 we performed a pedigree 
based study on 45 proven Lynch syndrome families diagnosed in a clinical setting. Fifty-two 
percent of 50% risk carriers opted for genetic testing. Testing was used more frequently by 
women (women vs. men 59% vs. 44%, p < 0.001) and by subjects with children (with children 
vs. without children 66% vs. 39%, p < 0.001). Hence, in a clinical setting a considerable portion 
of the risk carriers refrained from testing. Reasons for not testing may include a lack of informa-
tion, fear for cancer for themselves or their children, fear for screening procedures or fear for 
social discrimination. More data on the reasons of refraining of genetic testing are needed. Also, 
there is an important task for the professionals in the field to improve the implementation of 
genetic testing in clinical practice.
After identification of a mutation carrier colonoscopic surveillance can be offered to lower the 
risk for developing colorectal cancer. Currently, the surveillance is performed with white light 
colonoscopy, but with this technique 2-26% of adenomatous polyps are missed. Furthermore, 
flat and depressed adenomas are often invisible to white light endoscopy (WLE). Such lesions 
reportedly make up 36% of neoplasias in a standard population, and they are presumably more 
common in high-risk subjects. In chapter 7 we compared the diagnostic yield of white light 
endoscopy with autofluorescence endoscopy (AFE) for the surveillance of high-risk subjects. 
In total 75 high risk subjects, including 34 Lynch syndrome patients, were evaluated with 
both WLE and AFE. At least one adenoma was detected in 41 (55%) patients. WLE identified 
adenomas in 28 patients and AFE in 37 patients; corresponding with a 32% increase. In total 
95 adenomas were detected, 65 by WLE and 87 by AFE, resulting in a significantly higher 
sensitivity of AFE compared to WLE (92% vs. 68%; p = 0.001). The additionally detected 
adenomas with AFE were significantly smaller than the adenomas detected by WLE (mean 3.0 
mm vs. 4.9 mm, p < 0.01). The results of this study suggest that AFE may be preferable for the 
colonoscopic surveillance of high-risk patients.
The main findings of this thesis and directions for future research are discussed in chapter 8.
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Lynch syndroom is een erfelijk kanker syndroom dat wordt veroorzaakt door mutaties in de 
DNA herstel genen, MLH1, MSH2, MSH6 en PMS2. Dit syndroom wordt gekenmerkt door een 
hoog risico op het ontwikkelen van colorectaal carcinoom en endometrium carcinoom, maar 
ook andere soorten  kanker komen veelvuldig voor. Twee tot vijf procent van alle colorectaal 
carcinomen wordt veroorzaakt door het Lynch syndroom. De diagnostiek van Lynch syndroom 
wordt bemoeilijkt door het ontbreken van specifieke diagnostische kenmerken zoals het ontstaan 
van honderden poliepen in de darm. Tevens zijn de huidige klinische criteria niet optimaal voor 
de diagnostiek van Lynch syndroom. Er zijn nieuwe diagnostische strategieën nodig om Lynch 
syndroom families te kunnen identificeren.
De algemene doelen en achtergrond van dit proefschrift worden beschreven in hoofdstuk 1 
en in hoofdstuk 2 wordt een overzicht gegeven van de verschillende aspecten van Lynch syn-
droom. Hoofdstuk 3  beschrijft een studie waarin het risico van het ontwikkelen van colorectaal 
carcinoom en endometrium carcinoom gedurende het leven werd berekend. De studie-populatie 
bestond uit 67 Lynch syndroom families, totaal 246 bewezen mutatiedragers, die in de periode 
1994-2007 werden gezien op de afdeling Klinische Genetica van het Erasmus MC te Rotterdam. 
De resultaten van deze studie bevestigen het hoge risico voor het ontwikkelen van colorectaal 
carcinoom en endometrium carcinoom in Lynch syndroom. MLH1 mutatiedragers hadden het 
hoogste risico voor het ontwikkelen van colorectaal carcinoom (78% voor mannen en 57% voor 
vrouwen). Wat betreft het endometrium carcinoom hadden vrouwelijke MSH6 mutatiedragers 
het hoogste risico (61%). Eerdere studies hebben uitgewezen dat in 90% van de Lynch syndroom 
gevallen er een defect is in het MLH1 of MSH2 gen, terwijl er in 10% van de gevallen er sprake 
is van een mutatie in het MSH6 gen. In hoofdstuk 4 worden de resultaten beschreven van een 
studie waarin het aandeel van MSH6 mutaties wordt geëvalueerd. De studie populatie bestond 
uit 108 families die waren getest op een mutatie in de DNA herstel genen gedurende de periode 
2000-2006.  Van de 108 families bleken er 23 een mutatie te dragen (7 MLH1, 4 MSH2 en 12 
MSH6), hiervan had 53% een mutatie in het MSH6 gen. Daarnaast bleek dat de Amsterdam crite-
ria II de meerderheid van de MSH6 had gemist. De gereviseerde Bethesda criteria identificeerde 
de meerderheid van deze families, maar miste toch een aantal families met clustering van ‘late 
onset’ endometrium carcinoom. De resultaten van deze studie tonen aan dat de eerder gemelde 
incidentie van 10% MSH6 mutaties een onderschatting is. De identificatie van MSH6 mutatie 
families kan worden verbeterd door rekening te houden met het feit dat MSH6 mutaties vaker 
kunnen voorkomen in families waarin sprake is van clustering van endometrium carcinoom en 
colorectaal carcinoom op latere leeftijd. In hoofdstuk 5 wordt een studie beschreven waarin de 
bruikbaarheid van vijf verschillende voorspellende modellen voor de diagnostiek van Lynch 
syndroom wordt geëvalueerd. Voor deze studie werd de data van 321 families, inclusief 66 
mutatie families, gebruikt als input voor de modellen. Al de vijf modellen waren in staat om 
een goede onderscheid te maken tussen hoog en laag risico individuen. De Premm1,2 en de 
120
Samenvatting
Edinburgh model waren het beste in staat om de aanwezigheid van een mutatie te voorspellen, 
mede door het hoge discriminatief vermogen en een goede calibratie. Door het combineren van 
de voorspellende modellen met de resultaten van moleculaire analyse werd de specificiteit van 
de modellen verhoogd. Daarnaast bleek dat het gebruik van voorspellende modellen kan leiden 
tot lagere kosten in vergelijking met het verrichten van moleculaire analyse in alle colorectaal 
carcinomen. Echter is verdere evaluatie van de voorspellende modellen nodig alvorens imple-
mentatie in de klinische praktijk kan plaatsvinden. De identificatie van een mutatie kan leiden tot 
veel onrust binnen een familie. Kinderen van een bewezen mutatiedrager hebben een 50% kans 
op dragerschap. Als pre-symptomatische mutatie analyse negatief blijkt, dan hoeven individuen 
geen endoscopische surveillance te ondergaan. Hoofdstuk 6 beschrijft de resultaten van een 
studie naar het gebruik van pre-symptomatische mutatie analyse. Ongeveer de helft van de 50% 
risico dragers bleek gebruik te maken pre-symptomatische mutatie analyse. Het gebruik van pre-
synptomatische mutatie analyse was geassocieerd met het vrouwelijke geslacht (vrouwen vs. 
mannen 59% vs. 44%, p < 0.001) en het hebben van kinderen (met kinderen vs. zonder kinderen 
66% vs. 39%, p < 0.001). Desalniettemin liet een groot deel van de risico dragers zich niet 
testen. De reden hiervoor zijn onder andere angst voor de test procedure, gebrek aan informatie 
of de angst voor sociale discriminatie. Verder onderzoek naar het weigeren van mutatie analyse 
en een verbetering van het gebruik van pre-symptomatische mutatie analyse is noodzakelijk. Na 
de identificatie van een mutatie drager kan colonoscopische surveillance worden aangeboden 
om het risico op colorectaal carcinoom te verlagen. De huidige methode hiervoor is wit licht 
colonoscopie maar deze techniek is niet optimaal. Zo hebben eerdere studies uitgewezen dat 
2-26% van de adenomateuze poliepen worden gemist. Daarnaast is deze techniek niet goed in 
staat om vlakke adenomateuze poliepen op te sporen. Deze afwijkingen worden geacht vaker 
aanwezig te zijn in hoog risico patiënten. In hoofdstuk 7 hebben we de diagnostische waarde 
van wit licht colonoscopie (WLE) vergeleken met autofluorescentie colonoscopie (AFE). In deze 
studie werden 75 hoog risico individuen onderzocht met beide technieken. Eenenveertig (55%) 
personen bleken een of meer adenomateuze poliepen te hebben. Wit licht colonoscopie identifi-
ceerde een poliep in 28 individuen en autofluorescentie colonoscopie detecteerde een poliep in 
37 individuen, dit kwam overeen met een stijging van 32%. In totaal werden 95 adenomateuze 
poliepen ontdekt, 65 door WLE en 87 door AFE, wat correspondeert met een hogere sensitiviteit 
van AFE (92% vs. 68%, p = 0.001). De additioneel gevonden adenomen bleken ook nog eens 
een significante kleinere omvang te hebben (gemiddelde 3.0 mm vs. 4.9 mm, p < 0.01). De 
resultaten van deze studie suggereren dat AFE een betere techniek is voor de colonoscopische 
surveillance in deze hoog risico populatie. Tenslotte worden de belangrijkste bevindingen van 
dit proefschrift en aanwijzingen voor toekomstig onderzoek besproken in hoofdstuk 8.
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Centrum (opleider professor dr. J. van Saasse).
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